Note: Descriptions are shown in the official language in which they were submitted.
CA 02538864 2012-06-11
63198-1511
1
THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS
Field
The present invention relates to thalidomide analogs, methods of
synthesizing the analogs, and methods for using the analogs to modulate
angiogenesis and tumor necrosis factor alpha activities in a subject. More
particularly, the invention relates to sulfur-containing thalidomide analogs
and
methods of making and using the same.
Background
Thalidomide (N-a-phthalimidoglutarimide) is a glutamic acid derivative that
was introduced onto the market as a sedative hypnotic in 1956, but was
withdrawn in
1961 due to the development of severe congenital abnormalities in babies born
to
mothers using it for morning sickness. Interest in the agent was reawakened
after
thalidomide was found clinically effective in the treatment of erythema
nodosum
leprosum (ENL) and in the treatment of HIV wasting syndrome and various
cancers.
Mechanistic studies of its ENL activity demonstrated an anti-tumor necrosis
factor
alpha (anti-TNF-a) action. Specifically, thalidomide enhances the degradation
of TNF-
a RNA, and thereby lowers its synthesis and secretion. Further studies have
defmed it
to be a co-stimulator of both CD8+ and CD4+ T cells, an inhibitor of
angiogenesis via
its inhibitory actions on basic fibroblast growth factor (bFGF) and vascular
endothelial
growth factor (VEGF), and an inhibitor of the transcription factor, NFic13.
TNF-a and family members play pivotal roles in a variety of physiological and
pathological processes, which include cell proliferation and differentiation,
apoptosis,
the modulation of immune responses and induction of inflammation. TNF-a acts
via
two receptors, TNFR1 and 2. The former is expressed in all tissues and is the
predominant signaling receptor for TNF-a. The latter is primarily expressed on
immune cells and mediates more limited biological responses. The exposure of
cells to
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
2
TNF-cc can result in activation of a caspase cascade leading to cell death via
apoptosis.
Indeed, major cell surface molecules capable of initiating apoptosis are
members of the
TNF family of ligands and receptors. For example, death-inducing members of
the
TNF receptor family each contain a cytoplasmic 'death domain' (DD), which is a
protein-protein interaction motif critical for engaging downstream components
of the
signal transduction machinery.
Recently, TRAIL, the tumor necrosis factor-related apoptosis-inducing ligand,
has been shown to selectively induce apoptosis of tumor cells, but not most
normal
cells. It is indicated that TRAM mediates thymocyte apoptosis and is important
in the
induction of autoimmune diseases. More often, however, TNF-a receptor binding
induces the activation of transcription factors, AP-1 and NEKB, that
thereafter induce
genes involved in acute and chronic inflammatory responses. Overproduction of
TNF-
a has thus been implicated in many inflammatory diseases, such as rheumatoid
arthritis,
graft-versus-host disease and Crohn's disease, and it additionally exacerbates
ENL,
septic shock, AIDS and dementia associated with Alzheimer's disease (AD).
A number of thalidomide analogs optimized to reduce TNF-a synthesis have
been designed and synthesized. Primarily, these analogs include structural
modifications of the phthaloyl ring or glutarimide ring of thalidomide. In
addition,
following the demonstration that the anti-angiogenic property of thalidomide
is
associated with its hydroxylated, open-ring metabolites, syntheses of the
hydroxylated
and hydrolysis metabolites as inhibitors of angiogenesis or tumor metastasis
have been
reported. Although extensive studies exist regarding the structure-activity
relationships
between thalidomide and TNF'-a, very little is known about the contribution of
the four
amide carbonyl groups of thalidomide to its biological activity.
CA 02538864 2009-09-17
63198-1511
3
Summary
Thalidomide analogs having angiogenesis modulating activity and TNF-a
modulating activity are disclosed. In some embodiments, the disclosed
thalidomide
analogs are sulfur-analogs of thalidomide, its open-ring metabolites and its
derivatives (such as its hydroxylated derivatives) in which one or more
carbonyl
groups are replaced by thiocarbonyl groups. For example, in some embodiments,
thalidomide analogs wherein at least one carbonyl group on the pthaloyl moiety
or
on the glutaramide moiety (or its open ring form) of a thalidomide or a
thalidomide
analog is replaced by a thiocarbonyl group. In particular embodiments,
successive
replacement of the carbonyl groups in thalidomide with thiocarbonyl groups
provides thiothalidomide analogs having increased TNF-a inhibitory activity.
Surprisingly, the increase in TNF-a inhibition due to replacement of the
carbonyl
groups of thalidomide with thiocarbonyl groups is not associated with
toxicity.
Improved methods for making thalidomide and thalidomide analogs are also
disclosed, as are methods of converting thalidomide analogs into
thiothalidomides.
Due to their angiogenesis and TNF-a modulating activity, the disclosed
thalidomide
analogs, especially the disclosed thiothalidomides, can be used to treat a
subject
having a disease or condition related to angiogenesis or TNF-a activity, such
as a
tumor or unwanted neovascularization. Furthermore, the physical and
toxicological
properties of the disclosed thiothalidomide analogs make them suitable for
potently
and safely modulating angiogenesis and TNF-a activity without injection, for
example, by oral administration. This is in contrast to many currently
available
agents used for such purposes.
CA 02538864 2012-06-11
63198-1511
3a
According to one aspect of the present invention, there is provided a
compound, the compound having the formula:
R3 R2 / X
N¨
R4
R5
wherein X and Y are independently, oxygen or sulfur, each of R2-R5 is
independently
hydrogen, and R1 is
R12 R6 \R7 Or R19 R20
R11 R10 R9R8 Rig R17 n R15i=-16
wherein W and Z are each independently oxygen or sulphur; and further wherein
at
least two of X, Y, W and Z are sulphur; R6 and R7 are each independently,
alkoxy,
each of R5-R12 is independently hydrogen, R20 is hydrogen, and each of R15-R19
is
independently hydrogen;
CA 02538864 2009-09-17
63198-1511
3b
or a stereoisomer or pharmaceutically acceptable salt thereof.
,
According to another aspect of the present invention, there is
_
provided a pharmaceutical composition comprising the compounds described
herein or a pharmaceutically acceptable salt or stereoisomer thereof, which
may
be for oral administration.
According to still another aspect of the present invention, the
compounds described herein may be used for treating a disease treatable by
modulation of TNF-a activity or angiogenesis, for achieving an anti-tumor
effect,
for inhibiting tumor metastasis, for treating pathological angiogenesis or for
treating a neurodegenerative disease.
According to yet another aspect of the present invention, there is
provided a use of a compound having the formula:
R48
R47
X W OR2
R49 .
/
N
/
N z
=
,
R50 41/
R19
R15
Y
R18 R17 R16
R51
R52
or a pharmaceutically acceptable salt or stereoisomer thereof for treating a
disease treatable by modulation of TNF-a activity wherein X, Y, W and Z are
independently oxygen or sulphur; W, Z, R15-R20 are as defined for the compound
of formula (I) as described herein; and R47-R52 are each independently
hydrogen,
hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl,
substituted
alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy,
substituted
alkoxy, aryl, substituted aryl, amino, substituted amino, halogen or nitro.
This
compound may also be used for treating a disease treatable by modulation of
angiogenesis, for achieving an anti-tumor effect, for inhibiting tumor
metastasis,
for treating pathological angiogenesis or for treating a neurodegenerative
disease.
CA 02538864 2009-09-17
_
63198-1511
3c
According to a further aspect of the present invention, there is
,
provided a use of a compound having the formula:
R15
R16
4
R17
R2
N [CH .]
R3
/
n
IIP
Ri9 R18
N
=
R4
\ ICHd
X
R15
R16
R5
n
1110 R17
Rig
R18
or a pharmaceutically acceptable salt or stereoisomer thereof for treating a
5
disease treatable by modulation of TNF-a activity, wherein n=1-5; Xis oxygen
or
sulphur; and R2-R5 and R15-R19 are each independently hydrogen, hydroxyl,
acyl,
substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl,
alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy,
aryl,
substituted aryl, amino, substituted amino, halogen or nitro. This compound
may
also be used for treating a disease treatable by modulation of angiogenesis,
for
achieving an anti-tumor effect, for inhibiting tumor metastasis, for treating
pathological angiogenesis or for treating a neurodegenerative disease.
According to yet a further aspect of the present invention, there is
provided a use of a compound having the formula:
R2
R2
X
X
R3
/
IRP N
R5
[Cq
n
N \ 401 R3
'
,
R4
R4
Y
Y
R5
or a pharmaceutically acceptable salt or stereoisomer thereof for treating a
disease treatable by modulation of TNF-a activity, wherein each of X and Y are
CA 02538864 2009-09-17
63198-1511
3d
, independently oxygen or sulfur, n=1-5, and R2-R5 are
each independently
hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy,
alkyl,
_ substituted alkyl, alkenyl, substituted alkenyl,
alkynyl, substituted alkynyl, alkoxy,
substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen
or
nitro. This compound may also be used for treating a disease treatable by
modulation of angiogenesis, for achieving an anti-tumor effect, for inhibiting
tumor
metastasis, for treating pathological angiogenesis or for treating a
neurodegenerative disease.
According to still a further aspect of the present invention, there is
provided a use of a compound having the formula:
R54 R53
SNS
,
R55I
or a pharmaceutically acceptable salt or stereoisomer thereof for treating a
disease treatable by modulation of TNF-a activity wherein R53 and R54 are each
independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted
acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted
alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino,
substituted amino,
halogen or nitro; and R55 is hydrogen, alkyl, or substituted alkyl. This
compound
may also be used for treating a disease treatable by modulation of
angiogenesis,
for achieving an anti-tumor effect, for inhibiting tumor metastasis, for
treating
pathological angiogenesis or for treating a neurodegenerative disease.
According to another aspect of the present invention, there is
provided a use of a compound having the formula:
R2 S
R3 /
401 N¨R56
,
R4 R5 S
CA 02538864 2009-09-17
63198-1511
3e
or a pharmaceutically acceptable salt or stereoisomer thereof for treating a
disease treatable by modulation of TNF-a activity wherein R2-R5 are each
independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted
acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted
alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino,
substituted amino,
halogen or nitro; and R56 is hydrogen, alkyl or substituted alkyl. This
compound
may also be used for treating a disease treatable by modulation of
angiogenesis,
for achieving an anti-tumor effect, for inhibiting tumor metastasis, for
treating
pathological angiogenesis or for treating a neurodegenerative disease.
According to yet another aspect of the present invention, there is
provided a method for making thalidomide, comprising: reacting
N-(t-butoxycarbonyI)-L-glutamine and carbonyl diimidazole to provide
2,6-Dioxo-3-aminopiperidine; reacting the 2,6-Dioxo-3-aminopiperidine with
trifluoroacetic acid to provide 2,6-Dioxo-3-aminopiperidine trifluoroacetate;
and
reacting the 2,6-Dioxo-3-aminopiperidine trifluoroacetate with phthalic
anhydride
and triethylamine to provide thalidomide.
Brief Description of the Drawings
FIG. 1 is a bar graph showing the TNF-a inhibitory action of several
disclosed thalidomide analogs in murine cells having a luciferase reporter
element
plus the 3'-UTR of human TNF-a relative to their action in cells lacking the
3'-UTR.
FIG. 2 is a bar graph showing the relative angiogenic modulating
activity of 1,3¨Dioxo-2-(2-hydroxy-6-methoxypyridin-3-y1)-isoindoline
hydrobromide at several concentrations.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
4
FIG. 3 is a bar graph showing the relative angiogenic modulating activity of
2-(3-cyclohexeny1)-H-isoindo1-1,3(2H)-dithione at several concentrations.
FIG. 4 is a bar graph showing the relative angiogenic modulating activity of
1-(2,6-Dithioxo-3-piperidiny1)-1H-isoindole-1,3(211)-dione at several
concentrations.
FIG. 5 is a bar graph showing the relative angiogenic modulating activity of
3-Camphanic amino-2,6-piperidinedione at several concentrations.
FIG. 6 is a bar graph showing the relative angiogenic modulating activity of
Dithiophthalimide at several concentrations.
FIG. 7 is a bar graph showing the relative angiogenic modulating activity of
2-(1,3-Dihydro-1-oxo-3-thioxo-2H-isoindo1-2-y1)-pentanedioic acid at several
concentrations.
FIG. 8 is a bar graph showing the relative angiogenic modulating activity of
2-(2-0xo-6-thioxo-3-piperidiny1)-1H-isoindole-1,3(2H)-dione at several
concentrations.
FIG. 9 is a bar graph showing the relative angiogenic modulating activity of
2,3-Dihydro-3-thioxo-2-(2,6-dithioxo-3-piperidiny1)-1H-isoindo1-1-one at
several
concentrations.
FIG. 10 is a bar graph showing the relative angiogenic modulating activity of
2-Acetoxy-N-(2,6-dioxopiperidin-3-yl)benzamide at several concentrations.
FIG. 11 is a bar graph showing the relative angiogenic modulating activity of
1,3-Dioxo-2-(2,6-dimethoxypyridin-3-y1)-isoindoline at several concentrations.
Detailed Description of Particularly Disclosed Embodiments
I. Abbreviations
TNF-a ¨tumor necrosis factor alpha
CDI ¨ carboxyamidotriazole
ARE - adenylate/uridylate (AU)-rich element
UTR - untranslated region
THF ¨ tetrahydrofuran
NMR ¨ nuclear magnetic resonance
LR ¨ Lawesson's Reagent
WO 2005/028436 CA 02538864 2006-03-09 PCT/US2004/030506
5
Ii Terms
In order to facilitate an understanding of the embodiments presented, the
following explanations are provided.
The singular terms "a," "an," and "the" include plural referents unless
context
clearly indicates otherwise. Similarly, the word "or" is intended to include
"and"
unless the context clearly indicates otherwise. The term "comprises" means
"includes." Also, "comprising A or B" means including A or B, or A and B,
unless
the context clearly indicates otherwise. It is to be further understood that
all
molecular weight or molecular mass values given for compounds are approximate,
and are provided for description. Although methods and materials similar or
equivalent to those described herein can be used in the practice or testing of
this
disclosure, suitable methods and materials are described below. In addition,
the
materials, methods, and examples are illustrative only and not intended to be
limiting.
The term "subject" refers to animals, including mammals (for example,
humans and veterinary animals such as dogs, cats, pigs, horses, sheep, and
cattle).
An "R-group" or "substituent" refers to a single atom (for example, a
halogen atom) or a group of two or more atoms that are cOvalently bonded to
each
other, which are covalently bonded to an atom or atoms in a molecule to
satisfy the
valency requirements of the atom or atoms of the molecule, typically in place
of a
hydrogen atom. Examples of R-groups/substituents include alkyl groups,
hydroxyl
groups, alkoxy groups, acyloxy groups, mercapto groups, and aryl groups.
"Substituted" or "substitution" refer to replacement of a hydrogen atom of a
molecule or an R-group with one or more additional R-groups such as halogen,
alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto,
carboxy,
aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino,
morpholino,
piperidino, pyrrolidin-l-yl, piperazin-l-yl, nitro, sulfato or other R-groups.
"Alkyl" refers to a cyclic, branched, or straight chain group containing only
carbon and hydrogen, and unless otherwise mentioned typically contains one to
twelve carbon atoms. This term is further exemplified by groups such as
methyl,
ethyl, n-propyl, isobutyl, t-butyl, pentyl, pivalyl, heptyl, adamantyl, and
cyclopentyl.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
6
Alkyl groups can either be =substituted or substituted. "Lower alkyl" groups
are
those that contain one to six carbon atoms.
"Acyl" refers to a group having the structure RCO-, where R may be alkyl,
or substituted alkyl. "Lower acyl" groups are those that contain one to six
carbon
atoms.
"Acyloxy refers to a group having the structure RC00-, where R may be
alkyl or substituted alkyl. "Lower acyloxy" groups contain one to six carbon
atoms.
"Alkenyl" refers to a cyclic, branched or straight chain group containing only
carbon and hydrogen, and unless otherwise mentioned typically contains one to
twelve carbon atoms, and contains one or more double bonds that may or may not
be
conjugated. Alkenyl groups may be unsubstituted or substituted. "Lower
alkenyl"
groups contain one to six carbon atoms.
"Alkynyl" refers to a cyclic, branched or straight chain group containing
only carbon and hydrogen, and unless otherwise mentioned typically contains
one to
twelve carbon atoms, and contains one or more triple bonds. Alkynyl groups may
be unsubstituted or substituted. "Lower alkynyl" groups are those that contain
one
to six carbon atoms.
"Alkoxy" refers to a group having the structure R-0-, where R may be alkyl
or substituted alkyl. Examples of alkoxy groups include methoxy, ethoxy,
propoxy
and butoxy groups. "Lower alkoxy" groups are those that contain one to six
carbon
atoms.
The term "halogen" refers to fluor , bromo, chloro and iodo substituents.
"Aryl" refers to a monovalent unsaturated aromatic carbocyclic group having
a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or
anthryl),
which can optionally be unsubstituted or substituted.
The term "amino" refers to an R-group having the structure ¨NH2, which can
be optionally substituted with, for eXample, lower alkyl groups, to yield an
amino
group having the general structure ¨NHR or ¨NR2.
"Nitro" refers to an R-group having the structure ¨NO2.
The term "aliphatic" as applied to cyclic groups refers to ring structures in
which any double bonds that are present in the ring are not conjugated around
the
entire ring structure.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
7
The term "aromatic" as applied to cyclic groups refers to ring structures
which contain double bonds that are conjugated around the entire ring
structure,
possibly through a heteroatom such as an oxygen atom or a nitrogen atom. Aryl
groups, pyridyl groups and furan groups are examples of aromatic groups. The
conjugated system of an aromatic group contains a characteristic number of
electrons, for example, 6 or 10 electrons that occupy the electronic orbitals
making
up the conjugated system, which are typically un-hybridized p-orbitals.
"Pharmaceutical compositions" are compositions that include an amount (for
example, a unit dosage) of one or more of the disclosed compounds together
with
one or more non-toxic pharmaceutically acceptable excipients, including
carriers,
diluents, and/or adjuvants, and optionally other biologically active
ingredients. Such
pharmaceutical compositions can be prepared by standard pharmaceutical
formulation techniques such as those disclosed in Remington's Pharmaceutical
Sciences, Mack Publishing Co., Easton, PA (19th Edition).
A "therapeutically effective amount" of the disclosed compounds is a dosage
of the compound that is sufficient to achieve a desired therapeutic effect,
such as
inhibition of angiogenesis or an anti-tumor or anti-metastatic effect, or
inhibition of
TNF-a activity. In some examples, a therapeutically effective amount is an
amount
sufficient to achieve tissue concentrations at the site of action that are
similar to
those that are shown to modulate angiogenesis or TNF-a activity in tissue
culture, in
vitro, or in vivo. For example, a therapeutically effective amount of a
compound
may be such that the subject receives a dosage of about 0.1 pg/kg body
weight/day
to about 1000 mg/kg body weight/day, for example, a dosage of about 1 ,g/kg
body
weight/day to about 1000 gg/kg body weight/day, such as a dosage of about 5
g/kg
body weight/day to about 500 jig/kg body weight/day.
The term "stereoisomer" refers to a molecule that is an enatiomer,
diasteromer or geometric isomer of a molecule. Stereoisomers, unlike
structural
isomers, do not differ with respect to the number and types of atoms in the
molecule's structure but with respect to the spatial arrangement of the
molecule's
atoms. Examples of stereoisomers include the (+) and (-) forms of optically
active
molecules.
WO 2005/028436 CA 02538864 2006-03-09 PCT/US2004/030506
8
The term "modulate" refers to the ability of a disclosed compound to alter the
amount, degree, or rate of a biological function, the progression of a
disease, or
amelioration of a condition. For example, modulating can refer to the ability
of a
compound to elicit an increase or decrease in angiogenesis, to inhibit TNF-a
activity,
or to inhibit tumor metastasis or tumorigenesis.
The term "angiogenic activity" refers to the ability of a disclosed compound
or a particular concentration of a disclosed compound to stimulate
angiogenesis.
Angiogenic activity may be detected in vivo or in vitro. Angiogenic compounds
or
angiogenic concentrations of disclosed compounds stimulate angiogenesis, and
such
compounds and/or concentrations may be readily identified by those of ordinary
skill
in the art, using, for example, the methods described in the Examples that
follow.
The term "anti-angiogenic activity" refers to the ability of a compound or a
particular concentration of a disclosed compound to inhibit angiogenesis. Anti-
angiogenic activity may be detected in vivo or in vitro. Anti-angiogenic or
anti-
angiogenic concentrations of disclosed compounds inhibit angiogenesis, and
such
compounds and/or concentrations may be readily identified by those of ordinary
skill
in the art, using, for example, the methods described in the Examples that
follow.
III. Overview of Particularly Disclosed Embodiments
Disclosed are thalidomide analogs that modulate TNF-a activity and/or
angiogenesis, and as such can be used to treat a wide variety of pathological
conditions that are linked to angiogenesis and/or TNF-a activity.
Pharmaceutically
acceptable salts, stereoisomers, and metabolites of all of the disclosed
compounds
also are contemplated. In some embodiments, the thalidomide analogs are
thiothalidomide derivatives in which carbonyl groups in corresponding non-
sulfur-
containing thalidomide derivatives are replaced by one or more thiocarbonyl
groups.
In the structures that follow, all valency requirements are understood to be
satisfied. Thus, for example, carbon atoms have four bonds to other atoms,
even if
all such bonds are not shown. As is understood by those of ordinary skill in
the art,
where all four bonds to a carbon atom are not shown, additional bonds to
hydrogen
atoms are implied. Further substitution of such implied hydrogen atoms is
possible.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
9
In other embodiments, the disclosed compounds include compounds having
the chemical formula:
X
R3 /
N¨ Ri
R4
R5
wherein X and Y are independently CH2, oxygen or sulfur, and at least one of X
and
Y is sulfur if R1 does not include a sulfur atom; each of R2-Rs are
independently
hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy,
alkyl,
substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
alkoxy,
substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen,
nitro or
linked to form a five- or six-membered, unsubstituted or substituted,
aliphatic,
aromatic or heterocyclic ring, for example, hydrogen, lower alkyl, acyloxy,
halogen,
hydroxyl, amino or nitro such as hydrogen, acyloxy or hydroxyl; and R1 is an
unsubstituted or substituted, aliphatic or aromatic heterocyclic ring, an
unsubstituted
or substituted cycloalkenyl ring, or
R12 C- R6
-R7
R11 D D
µ10 µ9
wherein W and Z are each independently oxygen or sulfur, R6 and R7 are each
independently hydroxyl, alkoxy or substituted alkoxy, and each of R8-R12 are
independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted
acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted
alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino,
substituted amino,
halogen or nitro, for example, hydrogen, lower alkyl, acyloxy, halogen,
hydroxyl,
amino or nitro such as hydrogen, acyloxy or hydroxyl.
WO 2005/028436
CA 02538864 2006-03-09
PCT/US2004/030506
10
In particular embodiments, R1 is
R13
Rig ¨N R15 Z R14 R18.19
R17 R15 R16 R20 R15 R16, R19
R18 R17 ,
R1 R16 R15
R16
II R17
R17
Rig R18 , or R19
R18 ;
wherein W and Z are each independently oxygen or sulfur, R13 and R14 are each
independently hydrogen, alkyl or substituted alkyl; R20 is hydrogen, hydroxyl,
alkyl
or substituted alkyl such as aryl substituted alkyl; and R15-R19 are each
independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted
acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted
alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino,
substituted amino,
halogen or nitro, for example, hydrogen, lower alkyl, acyloxy, halogen,
hydroxyl,
amino or nitro such as hydrogen, acyloxy or hydroxyl. In some embodiments, at
least one of R2, R3, R4, R5, R8, R9, R10, R11, R15, R16, R17, R18 and R19 is
hydroxyl. In
other embodiments, at least one of X, Y, W and Z is sulfur, at least two of X,
Y, W
and Z are sulfur, or at least three of X, Y, W and Z are sulfur. For example,
in more
particular embodiments, X or Y is sulfur, and both W and Z are oxygen if
present;
both X and Y are sulfur and both W and Z are oxygen if present; X and Y are
both
oxygen and W or Z is sulfur if present; both X and Y are sulfur and W or Z is
sulfur
if present; or X or Y are sulfur and both W and Z are sulfur if present.
Alternatively,
where W and Z are present the following are possible: X=S, Y=0, W=0, Z=0;
X=0, Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0, Z=S; X=S,
Y=S, W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S; X=0, Y=0,
W=S, Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S, W=S, Z=0;
WO 2005/028436 CA 02538864 2006-03-09 PCT/US2004/030506
11
X=S, Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S, Z=S; or X=S,
Y=S, W=S, Z=S. In other particular embodiments X=S and Y=C112.
In more particular embodiments, the disclosed compounds have the formula
R3 100 X R12 C¨R6 ¨R7
R4 R5 y Ri 1Ri 0 R9 R8
wherein X, Y, W and Z are independently sulfur or oxygen and at least one of
X, Y,
W and Z is sulfur, and R2-R12 are as before. For example, in more particular
embodiments, X or Y is sulfur, and both W and Z are oxygen if present; both X
and
Y are sulfur and both W and Z are oxygen if present; X and Y are both oxygen
and
W or Z is sulfur if present; both X and Y are sulfur and W or Z is sulfur if
present;
or X or Y are sulfur and both W and Z are sulfur if present. Alternatively,
where W
and Z are present the following are possible: X=S, Y=0, W=0, Z=0; X=0, Y=S,
W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0, Z=S; X=S, Y=S, W=0,
Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S; X=0, Y=0, W=S, Z=S;
X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S, W=S, Z=0; X=S, Y=S,
W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S, Z=S; or X=S, Y=S, W=S,
Z=S. In more particular embodiments, at least one of R2-R5 and R8-R11 is
hydroxyl.
Specific examples of such compounds include:
OH s COOMe HO COOMe
= N zCOOMe = N¨( zCOOMe
and
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
12
In other more particular embodiments, the disclosed compounds have the
chemical formula:
X
R3 =
R20
R4 N''
\y;:>19 "
R5 Rig z
R17 R15
R16
wherein W, X, Y and Z each are independently sulfur or oxygen and at least one
of
W, X, Y and Z is sulfur; and R2-R5 and R15-R20 are as before. For example, in
more
particular embodiments, X or Y is sulfur, and both W and Z are oxygen; both X
and
Y are sulfur and both W and Z are oxygen; X and Y are both oxygen and W or Z
is
sulfur; both X and Y are sulfur and W or Z is sulfur; or X or Y are sulfur and
both
W and Z are sulfur. Alternatively, the following are possible: X=S, Y=0, W=0,
Z=0; X=0, Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0, Z=S;
X=S, Y=S, W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S; X=0,
Y=0, W=S, Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S,
W=S, Z=0; X=S, Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=-0, Y=S, W=S, Z=S;
or X=S, Y=S, W=S, Z=S. In more particular embodiments, at least one of R2-R5
and R15-R19 is hydroxyl. Specific examples of such compounds include:
S S 0 S
\ NH NH
N N
OH 0 HO
and
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
13
The disclosed compounds also include compounds having the formula
R22 R21
R23 is
R24 R26
R25 V
wherein T and V are independently oxygen or sulfur, R21-R25 are independently
hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy,
alkyl,
substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
alkoxy,
substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen
or nitro,
for example, hydrogen, lower alkyl, acyloxy, halogen, hydroxyl, amino or nitro
such
as hydrogen, acyloxy or hydroxyl; and R26 is
E13
R20 R1 R16
¨N R>1\l/
-19
Z R14 R17
Rig
R17 R15
R16 R15 R16 , R19 Rig
R1 R16 Ri R16
II R17 41 R17
R19 Rig Rig ;
, or R19
wherein W, Z and R13-R20 are as before. For example, in more particular
embodiments, T or V is sulfur, and both W and Z are oxygen if present; both T
and
V are sulfur and both W and Z are oxygen if present; T and V are both oxygen
and
W or Z is sulfur if present; both T and V are sulfur and W or Z is sulfur if
present; or
T or V are sulfur and both W and Z are sulfur if present. Alternatively, where
W
and Z are present the following are possible: T=0, V=0, W=0, Z=0; T=S, V=0,
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
14
W=0, Z=0; T=0, V=S, W=0, Z=0; TO, V=0, W=S, Z=0; T=0, V=0, W=0,
Z=S; T=S, V=S, W=0, Z=0; T=S, V=0, W=S, Z=0; T=S, V=0, W=0, Z=S; T=0,
V=0, W=S, Z=S; T=0, V=S, W=0, Z=S; T=0, V=S, W=S, Z=0; T=S, V=S, W=S,
Z=0; T=S, V=S, W=0, Z=S; T=S, V=0, W=S, Z=S; T=0, V=S, W=S, Z=S; or
T=S, V=S, W=S, Z=S. In some embodiments, at least one of R15-R19 and R22-R26
is
hydroxyl.
Still further, the disclosed compounds include compounds having the
formula
R32 R31
R33 R30
R20
R28D
R27134 W
R20
>N1/
Rig
R18
R17 R15
R16
wherein X, Y are each independently oxygen or sulfur; W, X and R15-R20 are as
before; R27-R33 are each independently hydrogen, hydroxyl, acyl, substituted
acyl,
acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted
alkenyl,
alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted
aryl,
amino, substituted amino, halogen or nitro, for example, hydrogen, lower
alkyl,
acyloxy, halogen, hydroxyl, amino or nitro such as hydrogen, acyloxy or
hydroxyl;
and R34 is hydrogen, alkyl or substituted alkyl. For example, in more
particular
embodiments, X or Y is sulfur, and both W and Z are oxygen; both X and Y are
sulfur and both W and Z are oxygen; X and Y are both oxygen and W or Z is
sulfur;
both X and Y are sulfur and W or Z is sulfur; or X or Y are sulfur and both W
and Z
are sulfur. Alternatively, the following are possible: X=0, Y=0, W=0, Z=0;
X=S,
Y=0, W=0, Z=0; X=0, Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0,
W=0, Z=S; X=S, Y=S, W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0,
Z=S; X=0, Y=0, W=S, Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S,
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
15
Y=S, W=S, Z=0; X=S, Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S,
Z=---S; or X=S, Y=S, W=S, Z=S.
In addition, the disclosed compounds include compounds having the formula
R6 X
ID 37 0
R35
R38 R314. W
R39 I N N z
R20
y R19
R18 K17,_, R15R16 6
wherein X and Y are each independently oxygen or sulfur; W, Z, R15-R20 and R34
are
as before, R35 is alkyl or substituted alkyl, and R36-R39 are each
independently
hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy,
alkyl,
substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
alkoxy,
substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen
or nitro,
for example, hydrogen, lower alkyl, acyloxy, halogen, hydroxyl, amino or nitro
such
as hydrogen, acyloxy or hydroxyl. For example, in more particular embodiments,
X
or Y is sulfur, and both W and Z are oxygen; both X and Y are sulfur and both
W
and Z are oxygen; X and Y are both oxygen and W or Z is sulfur; both X and Y
are
sulfur and W or Z is sulfur; or X or Y are sulfur and both W and Z are sulfur.
Alternatively, the following are possible: X=0, Y=0, W=0, Z=0; X=S, Y=0,
W=0, Z=0; X=0, Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0,
Z=S; X=S, Y=S, W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S;
X=0, Y=0, W=S, Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S,
W=S, Z=0; X=S, Y=S, W=0, Z=S; X=S, Y=0, W=S, S; X=0, Y=S, W=S, Z=S;
or X=S, Y=S, W=S, Z=S.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
16
Other embodiments include compounds having the formula
R41 R40 X W\ /R20
R4
R43 Rig R15
R44 R45 y R18 R17R16
wherein X and Y each are independently oxygen or sulfur; W, Z and R15-R20 are
as
before; and R40-R-45 are each independently hydrogen, hydroxyl, acyl,
substituted
acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl,
substituted
alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl,
substituted
aryl, amino, substituted amino, halogen or nitro, for example, hydrogen, lower
alkyl, acyloxy, halogen, hydroxyl, amino or nitro such as hydrogen, acyloxy or
hydroxyl. For example, in more particular embodiments, X or Y is sulfur, and
both
W and Z are oxygen; both X and Y are sulfur and both W and Z are oxygen; X and
Y are both oxygen and W or Z is sulfur; both X and Y are sulfur and W or Z is
sulfur; or X or Y are sulfur and both W and Z are sulfur. Alternatively, the
following are possible: X=0, Y=0, W=0, Z=0; X=S, Y=0, W=0, Z=0; X=0,
Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0, Z=S; X=S, Y=S,
W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S; X=0, Y=0, W=S,
Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S, W=S, Z=0; X=S,
Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S, Z=S; or X=S, Y=S,
W=S, Z=S.
The disclosed compounds further include compounds having the formula
*13
R2 x w
R3
Z R14
R4
R5 y R16 R15
wherein X, Y, W and Z are independently oxygen or sulfur, and R2-R5 and R13-
R16
are as before. For example, in more particular embodiments, X or Y is sulfur,
and
both W and Z are oxygen; both X and Y are sulfur and both W and Z are oxygen;
X
and Y are both oxygen and W or Z is sulfur; both X and Y are sulfur and W or Z
is
WO 2005/028436
CA 02538864 2006-03-09
PCT/US2004/030506
17
sulfur; or X or Y are sulfur and both W and Z are sulfur. Alternatively, the
following are possible: X=0, Y=0, W=0, Z=0; X=S, Y=0, W=0, Z=0; X=0,
Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0, Z=S; X=S, Y=S,
W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S; X=0, Y=0, W=S,
Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S, W=S, Z=0; X=S,
Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S, Z=S; or X=S, Y=S,
W=S, Z=S.
Also disclosed is a thalidomide analog compound having the formula
R15 X
R16 N- R20
R3 R R172 R18 y
wherein X, Y and Z are independently oxygen or sulfur, and R2-R5, R15-R20 and
R34R4 140 R5 N- R34
are as before. For example, in more particular embodiments, X or Y is sulfur,
and Z
is oxygen; both X and Y are sulfur and Z is oxygen; X and Y are both oxygen
and Z
is sulfur. Alternatively, the following are possible: X=0, Y=0, Z=0; X=S, Y=0,
Z=0; X=0, Y=S, Z=0; X=0, Y0, Z=S; X=S, Y=S, Z=0; X=S, Y=0, Z=S; X=0,
Y=S, Z=S; or X=S, Y=S, Z=S.
Also disclosed is a thalidomide analog compound having the formula
NLJ\XN-Ri
wherein X and Y are independently oxygen or sulfur, and R1, R2, R4 and R5 are
as R4 R5
before. For example, in particular embodiments, R1 is
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
18
113
\n/R20 R1 R16
--N Z Ri4 Rig 411 R17
R18 rci7 R15
R16 R15 9 R16 Rig R18 9
R15 R16 R1 R16
II R17 11 R17
R19 R18 , or R19 R18 ;
wherein W, Z, and R13-R20 are as before. For example, in more particular
embodiments, X or Y is sulfur, and both W and Z are oxygen if present; both X
and
Y are sulfur and both W and Z are oxygen if present; X and Y are both oxygen
and
W or Z is sulfur if present; both X and Y are sulfur and W or Z is sulfur if
present;
or X or Y are sulfur and both W and Z are sulfur if present. Alternatively,
where W
and Z are present the following are possible: X=0, Y=0, W=0, Z=0; X=S, Y=0,
W=0, Z=0; X=0, Y=S, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0,
Z=S; X=S, Y=S, W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S;
X=0, Y=0, W=S, Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, Z=0; X=S,
Y=S, W=S, Z=0; X=S, Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S,
Z=S; or X=S, Y=S, W=S, Z=S. In more particular embodiments, the compound has
the formula:
113
X W
¨N
Z R14
R5 Y R16 R15
wherein X, Y are independently oxygen or sulfur, and W, Z, R2, R4, R5, and
R13-R16 are as before. For example, in more particular embodiments, X or Y is
sulfur, and both W and Z are oxygen; both X and Y are sulfur and both W and Z
are
WO 2005/028436 CA 02538864 2006-03-09
PCT/US2004/030506
19
oxygen; X and Y are both oxygen and W or Z is sulfur; both X and Y are sulfur
and
W or Z is sulfur; or X or Y are sulfur and both W and Z are sulfur.
Alternatively,
the following are possible: X=0, Y=0, W=0, Z=0; X=S, Y=0, W=0, Z=0; X=0,
YS, W=0, Z=0; X=0, Y=0, W=S, Z=0; X=0, Y=0, W=0, Z=S; X=S, Y=S,
W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S; X0, Y0, w=s,
Z=S; x=o, YS, im=o, Z=S; X=0, Y=S, W=S, Z=0; X=S, Y=S, W=S, Z=0; X=S,
Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S, Z=S; or X=S, Y=S,
W=S, Z=S. In even more particular embodiments, at least one of R2, R4, R5, R15
and
R16 is hydroxyl.
Also disclosed is a compound having the formula:
R3 0
R4 R46
R5 D
wherein G and D are each independently oxygen or sulfur, R2-R5 are as before,
and
R46 is
R13
R19 R20 wI ----N Z R14
R1 8ZR17 IR16 R15z or R16 R15
wherein W, Z and R13-R20 are as before. For example, in particular
embodiments, G
or D is sulfur, and both W and Z are oxygen; both G and D are sulfur and both
W
and Z are oxygen; G and D are both oxygen and W or Z is sulfur; both G and D
are
sulfur and W or Z is sulfur; or G or D are sulfur and both W and Z are sulfur.
Alternatively, the following are possible: G-0, D=0, W=0, Z=0; G=S,
W=0, Z=0; G=0, D=S, W=0, Z=0; G=0, D=0, W=S, Z=0; G=0, D=0, W=0,
Z=S; G=S, D=S, W=0, Z=0; G-S, D=0, W=S, Z=0; G=S, D=0, W=0, Z=S;
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
20
G=0, D=0, W=S, Z=S; G=0, D=S, W=0, Z=8; G=0, D=S, W=S, Z=0; G=S,
D=S, W=S, Z=0; G¨S, D=S, W=0, Z=S; G=S, D=0, W=S, Z=S; G=0, D=S, W=S, .
Z=S; or G=S, D=S, WS, Z=S.
A method for modulating TNF-a activity in a subject also is disclosed. The
method includes administering to the subject a therapeutically effective
amount of
one or more of any of the compounds disclosed above, or a compound having the
formula:
R48 R47
__X W R z -20
R49 \ N
N Z
R50 ii R19 R15
Y R18 R17R16
R51 R52
where X and Y are independently oxygen or sulfur; W, Z, R15-R20 are as before;
and
R47-R52 are each independently hydrogen, hydroxyl, acyl, substituted acyl,
acyloxy,
substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl,
alkynyl,
substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl,
amino,
substituted amino, halogen or nitro, for example, hydrogen, lower alkyl,
acyloxy,
halogen, hydroxyl, amino or nitro such as hydrogen, acyloxy or hydroxyl;
or a compound having the formula
R15 R16
R3 . / - n R2 N¨ C H2 R19 11 R17 R18
N\ R15 R16
R4 R5 X 1-12 n . R17
R19 R18
wherein n=1-5; X is oxygen or sulfur; and R2-R5 and R15-R19 are as before;
or a compound having the formula:
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
21
R2=X X
R3 R3
==-1 n
R4 N N # R4
R5 R5
wherein each of X and Y are independently oxygen or sulfur, n=1-5, and R2-R5
are
as before;
or a compound having the formula:
R54 R53
N S
R55
wherein R53 and R54 are independently hydrogen, hydroxyl, acyl, substituted
acyl,
acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted
alkenyl,
alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted
aryl,
amino, substituted amino, halogen or nitro, for example, hydrogen, lower
alkyl,
acyloxy, halogen, hydroxyl, amino or nitro such as hydrogen, acyloxy or
hydroxyl
;and R55 is hydrogen, alkyl, or substituted alkyl; or a compound having the
formula:
R2
N¨ R56
R3 40
R4
R5
wherein R2-R5 are as before and R56 is hydrogen, alkyl or substituted alkyl;
or pharmaceutically acceptable salts or stereoisomers thereof.
Novel thio-substituted analogs having the structures described with respect
to the method above also are contemplated. For example, in more particular
embodiments, X or Y is sulfur, and both W and Z are oxygen if present; both X
and
Y are sulfur and both W and Z are oxygen if present; X and Y are both oxygen
and
W or Z is sulfur if present; both X and Y are sulfur and W or Z is sulfur if
present;
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
22
or X or Y are sulfur and both W and Z are sulfur if present. Alternatively, if
W and
Z are present, the following are possible: X=0, Y=0, W=0, Z=0; X=S, Y=0,
W-0, Z-0; X-0, Y¨S, W-0, Z-0, X-0, Y-0, W¨S, Z-0; X=0, Y=0, W=0,
Z=S; X=S, Y=S, W=0, Z=0; X=S, Y=0, W=S, Z=0; X=S, Y=0, W=0, Z=S;
X=0, Y=0, W=S, Z=S; X=0, Y=S, W=0, Z=S; X=0, Y=S, W=S, .Z=0; X=S,
Y=S, W=S, Z=0; X=S, Y=S, W=0, Z=S; X=S, Y=0, W=S, Z=S; X=0, Y=S, W=S,
Z=S; or X=S, Y=S, W=S, Z=S.
Particularly disclosed compounds and compounds that can be used in the
disclosed methods include one or more compounds having the following
structures:
00
NH
COOMe
N--c /COOMe
0
=
= 0 0
0 0 00
N
0
= 0
COOMe 0 0
/COOMe INLIaL
= 0
0 0
N 0,
0 = 0 0
COOH = s S
001 N 0 NH
/COOH N S
0 =
0 S 0
NNH 0
0
0
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
23
0
5ocH3 o 0 o
0
0 H .__ N /
0 N ¨.S lel N
0
0N
N
0 0 0
0 0 0 OMe 0 HO
/ N
=
0 I OMe I. N--- 1\1,-0Me HBr
S 0
/
0 N-0 OHO
S OMe
i N / i N
S 0
41111 41 ,--0Me
S S 0
S
0 NH ----(NH
S ---\( S 0
0 0
0 OMe = 0
illill NH 0
410 N / --0Me .1 NH
OH
0 0
0 0
0 0
0 N7\7N 410
0 0
0
Still further, a method for modulating angiogenesis in a subject is disclosed.
The method includes administering to the subject a therapeutically effective
amount
of one or more of any of the disclosed compounds. Examples of compounds useful
for the method are shown above. In some embodiments, where an anti-angiogenic
compound or an anti-angiogenic concentration of a compound is utilized, the
therapeutically effective amount of the compound can be administered to a
subject
with a tumor to achieve an anti-tumor effect, such as inhibition of
tumorigenesis or
tumor metastasis. In other embodiments, the therapeutically effective amount
of the
compound is administered to a subject with a pathological angiogenesis.
Alternatively, where stimulation of angiogenesis is desired an angiogenic
compound
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
24
or an angiogenic concentration of a compound is administered to a subject to
stimulate angiogenesis.
As angiogenesis inhibitors, the disclosed compounds are useful in the
treatment of both primary and metastatic solid tumors, including carcinomas of
breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach,
pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract
(including
kidney, bladder and urothelium), female genital tract, (including cervix,
uterus, and
ovaries as well as choriocarcinoma and gestational trophoblastic disease),
male
genital tract (including prostate, seminal vesicles, testes and germ cell
tumors),
endocrine glands (including the thyroid, adrenal, and pituitary glands), and
skin, as
well as hemangiomas, melanomas, sarcomas (including those arising from bone
and
soft tissues as well as Kaposi's sarcoma) and tumors of the brain, nerves,
eyes, and
meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas,
neuromas, neuroblastomas, Schwarmomas, and meningiomas). Such compounds
may also be useful in treating solid tumors arising from hematopoietic
malignancies
such as leukemias (i.e. chloromas, plasmacytomas and the plaques and tumors of
mycosis fimgoides and cutaneous T-cell lymphoma/leukemia) as well as in the
treatment of lymphomas (both Hodgkin's and non-Hodgkin's lymphomas). In
addition, these compounds may be useful in the prevention of metastases from
the
tumors described above either when used alone or in combination with
radiotherapy
and/or other chemotherapeutic agents.
Further uses of disclosed anti-angiogenic compounds/concentrations include
the treatment and prophylaxis of autoimmune diseases such as rheumatoid,
immune
and degenerative arthritis. Such compounds can also be used to treat a
pathological
(i.e. abnormal, harmful or undesired) angiogenesis, for example, various
ocular
diseases such as diabetic retinopathy, retinopathy of prematurity, corneal
graft
rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal
neovascularization due to macular degeneration, hypoxia, angiogenesis in the
eye
associated with infection or surgical intervention, and other abnormal
neovascularization conditions of the eye; skin diseases such as psoriasis;
blood
vessel diseases such as hemagiomas, and capillary proliferation within
atherosclerotic plaques; Osler-Webber Syndrome; myocardial angiogenesis;
plaque
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
25
neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and
wound
granulation. Other uses include the treatment of diseases characterized by
excessive
or abnormal stimulation of endothelial cells, including but not limited to
intestinal
adhesions, Crohn's disease, atherosclerosis, sclerodenna, and hypertrophic
scars,
such as keloids. Another use is as a birth control agent, by inhibiting
ovulation and
establishment of the placenta. The disclosed compounds are also useful in the
treatment of diseases that have angiogenesis as a pathologic consequence such
as
cat scratch disease (Rochele minalia quintosa) and ulcers (Helicobacter
pylori). The
disclosed compounds are also useful to reduce bleeding by administration prior
to -
surgery, especially for the treatment of resectable tumors.
Angiogenic compounds or angiogenic concentrations of disclosed compound
can be used can be used to treat a variety of conditions that would benefit
from
stimulation of angiogenesis, stimulation of vasculogenesis, increased blood
flow,
and/or increased vascularity. Particular examples of conditions and diseases
amenable to treatment using disclosed angiogenic compounds, or angiogenic
concentrations of disclosed compounds, include any condition associated with
an
obstruction of a blood vessel, such as obstruction of an artery, vein, or of a
capillary
system. Specific examples of such conditions or disease include, but are not
necessarily limited to, coronary occlusive disease, carotid occlusive disease,
arterial
occlusive disease, peripheral arterial disease, atherosclerosis, myointimal
hyperplasia (such as due to vascular surgery or balloon angioplasty or
vascular
stenting), thromboangiitis obliterans, thrombotic disorders, vasculitis, and
the like.
Examples of conditions or diseases that may be prevented using the disclosed
angiogenic compounds/concentrations include, but are not limited to, heart
attack
(myocardial infarction) or other vascular death, stroke, death or loss of
limbs
associated with decreased blood flow, and the like. Other therapeutic uses for
angiogenesis stimulation according to the disclosure include, but are not
necessarily
limited to accelerating healing of wounds or ulcers; improving the
vascularization of
skin grafts or reattached limbs so as to preserve their function and
viability;
improving the healing of surgical anastomoses(such as in re-connecting
portions of
the bowel after gastrointestinal surgery); and improving the growth of skin or
hair.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
26
Yet further, a method for inhibiting TNF-a activity in a subject using the
disclosed compounds is provided. The method includes administering a
therapeutically effective amount of a disclosed compound to a subject to
achieve a
TNF-a inhibitory effect. The disclosed compounds having TNF-a inhibitory
effects
are useful for treating many inflammatory, infectious, immunological, and
malignant diseases. These include but are not limited to septic shock, sepsis,
endotoxic shock, hemod3mamic shock and sepsis syndrome, post ischemic
reperfusion injury, malaria, mycobacteiial infection, meningitis, psoriasis
and other
dermal diseases, congestive heart failure, fibrotic disease, cachexia, graft
rejection,
cancer, tumor growth, undesirable angiogenesis, autoimmune disease,
opportunistic
infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis,
osteoarthritis,
other arthritic conditions, inflammatory bowel disease, Crohn's disease,
ulcerative
colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy,
radiation
damage, and hyperoxic alveolar injury. In addition, the compounds can be used
to
treat other neurodegenerative diseases as exemplified by Alzheimer's disease,
Parkinson's disease, head trauma, stroke and ALS.
The disclosed compounds can be used in combination with other
compositions and procedures for the treatment of diseases. For example, a
tumor
can be treated conventionally with surgery, radiation or chemotherapy in
combination with an anti-angiogenic compound/concentration and then,
optionally
the compound/concentration can be further administered to the subject to
extend the
dormancy of micrometastases and to stabilize and inhibit the growth of any
residual
primary tumor. Alternatively, an angiogenic compound or angiogenic
concentration
of a compound can be used in combination with other angiogenesis stimulating
agents. For example, thermal energy (in the form of resistive heating, laser
energy
or both) to create thermally treated stimulation zones or pockets (optionally
interconnected, at least initially, by small channels) in the tissue for the
introduction
of blood born growth and healing factors, along with stimulated capillary
growth
surrounding the thermally treated zones. Such stimulation zones allow
increased
blood flow to previously ischemic and/or nonfunctional tissue (such as cardiac
tissue) with a concomitant increased supply of oxygen and nutrients ultimately
resulting in a revitalization of the treated sections the tissue when used in
CA 02538864 2012-06-11
63198-1511
27
combination with the angiogenic compositions/concentrations. In other
embodiments, disclosed compounds exhibiting TNF-a inhibitory activity can be
combined with other TNF-a inhibitory agents, for example, steroids such as
dexamethasone and prednisolone. When used for treatment of a cancer, the
compounds can be used in combination with chemotherapeutic agents and/or
radiation and/or surgery.
Examples of other chemotherapeutic agents that can be used in combination
with the disclosed compounds include alkylating agents, antimetabolites,
natural
products, kinase inhibitors, hormones and their antagonists, and miscellaneous
other
agents. Examples of alkylating agents include nitrogen mustards (such as
mechlorethamine, cyclophosphamide, melphalan, uracil mustard or chlorambucil),
alkyl sulfonates (such as busulfan), and nitrosoureas (such as carmustine,
lomustine,
semustine, streptozocin, or dacarbazine). Examples of antimetabolites include
folic T M
acid analogs (such as methotrexate), pyrimidine analogs (such as 5-FU or
cytarabine), and purine analogs, such as mercaptopurine or thiog,uanine.
Examples
of natural products include vinca alkaloids (such as vinblastine, vincristine,
or
vindesine), epipodophyllotoxins (such as etoposide or teniposide), antibiotics
(such
as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or
mitocycin
C), and enzymes (such as L-asparaginase). Examples of ldnase inhibitors
include
small molecule inhibitors (such as Iressa, Tarceva; PKI-166, CI-1033, CGP-
5923A,TM TM
EKB-569, TAK165, GE-572016, CI-1033, SU5416, ZD4190, PTK787/ZK222584,
CGP41251, CEP-5214, ZD6474, B1BF1000, VGA1102, SU6668, SU11248, CGP-
57148, tricyclic quinoxalines, SU4984, SU5406, GleeveTCM, NSC680410, PD166326,
PD1173952, CT53518, GTP14564, PKC412, PP1, PD116285, CGP77675,
CGP76030, CEP-701, and CEP2583), ligand modulators (such as Bevacizumanb,
MV833, Soluble Flt-1 and Flk-1, VEGF Trap, GFB 116, NM3, VEGF 121-diptheria
toxin conjugate and Interfereon-a), and monoclonal antibodies against
receptors
(such as Cetaximab, ABX-EGF, Y10, MDX-447, h-R3, EMD 72000, herceptin,
MDX-H210, pertuzumab, IMC-1C11, and MF1). Examples of hormones and
antagonists include adrenocorticosteroids (such as prednisone), progestins
(such as
hydroxyprogesterone caproate, medroxyprogesterone acdtate, and magestrol
acetate), estrogens (such as diethylstilbestrol and ethinyl estradiol),
antiestrogens
CA 02538864 2012-06-11
63198-1511
28
(such as tamoxifen), and androgens (such as testerone proprionate and
fluoxyrnesterone). Examples of miscellaneous agents include platinum
coordination
complexes (such as cis-diamine-dichloroplatinum II, which is also known as
cisplatin), substituted ureas (such as hydroxyurea), methyl hydrazine
derivatives
(such as procarbazine), vaccines (such as APC8024), AP22408, B43-genistein
conjugate, paclitaxel, AG538, and adrenocrotical suppressants (such as
mitotane and
aminoglutethimide). In addition, the disclosed compounds can be combined with
gene therapy approaches, such as those targeting VEGF/VEGFR (including
antisense oligonucleotide therapy, Adenovirus-based Flt-1 gene therapy,
Retrovirus-
base Flk-1 gene therapy, Retrovirus-based VHL gene therapy, and angiozyme) and
IGF-1R (including INX-4437). Examples of the most commonly used
chemotherapy drugs that can be used in combination with the disclosed
tricyclic
compounds agent include Adriamycin, Alkeran, Ara-C, BiCNU, Busulfan, CCNU,
Carboplatinum, Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU, Fludarabine,
Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin,
im
Mitoxantrone, Nitrogen Mustard, Taxol, Velban, Vincristine, VP-16, Gemcitabine
TM TM
(Gemzar), Herceptin, Irinotecan (Camptosar, CPT-11), Leustatin, Navelbine,
Rituxan STI-571, Taxotere, Topotecan (Hycamtin), Xeloda (Capecitabine),
Zevelin
and calcitriol.
The disclosed compounds also can be combined with radiotherapy
employing radioisotopes (such as 32/3, 90y, 1251, 1311, an 177a Lu),
particle beams (such
as proton, neutron and electron beams) and electromagnetic radiation (such as
gamma rays, x-rays and photodynamic therapy using photosensitizers and visible
or
ultraviolet rays).
Additionally, the disclosed compounds can be combined with
pharmaceutically acceptable excipients, and optionally sustained-release
matrices,
such as biodegradable polymers, to form therapeutic compositions. Therefore,
also
disclosed are pharmaceutical compositions including one or more of any of the
compounds disclosed above and a pharmaceutically acceptable carrier. The
composition may comprise a unit dosage form of the composition, and may
further
comprise instructions for administering the composition to a subject to
inhibit
angiogenesis, for example, instructions for administering the composition to
achieve
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
29
an anti-tumor effect or to inhibit a pathological angiogenesis. In particular
embodiments, the pharmaceutical composition may comprise one or more of 1-
Thioxo-3-oxo-2-(2-oxo-6-thioxopiperidin-3-yl)isoindoline, 1,3-Dioxo-2-(2,6-
dithioxopiperidin-3-ypisoindoline, 1-Thioxo-3-oxo-2-(2,6-dithioxopiperidin-3-
yl)isoindoline, N-(2,6-dioxopiperidin-3-y1)-2,3-naphthalenedicarboxamide, 1,3-
Dioxo-2-(2,6-dioxopiperidin-3-y1)-5-azaisoindoline, 1,3-Dioxo-2-(1-phenethy1-
2,6-
dioxopiperidin-3-yl)isoindoline, 2-Acetoxy-N-(2,6-dioxopiperidin-3-
yl)benzamide,
2-(2-0xo-6-thioxo-3-piperidiny1)-1H-isoindole-1,3(2H)-dione, Dimethyl 2-(1,3-
dihydro-1-oxo-3-thioxo-2H-isoindo1-2-y1)-pentanedioate, Dimethyl 2-(1,3-
dihydro-
1,3-dithioxo-2H-isoindo1-2-y1)-pentanedioate, 2-(1,3-Dihydro-1-oxo-3-thioxo-2H-
isoindo1-2-y1)-pentanedioic acid, 2,3-Dihydro-3-thioxo-2-(2,6-dioxo-3-
piperidiny1)-
1H-isoindo1-1-one, 2-(2, 6-Dithioxo-3-piperidiny1)-1H-isoindole-1,3(2H)-dione,
2,3-Dihydro-3-thioxo-2-(2-oxo-6-thioxo-3-piperidiny1)-1H-isoindol-l-one, 2,3-
Dihydro-3-thioxo-2-(2,6-dithioxo-3-piperidiny1)-1H-isoindol-l-one, 2-(3-
Cyclohexeny1)-1H-isoindo1-1,3(211)-dithione, 2-(3-Cyclohexeny1)-1H-isoindole-
1,3(2H)-dione, 2-(3-Cyclohexeny1)-1H-isoindo1-1,3(2H)-dithione, 2,3-Dihydro-3-
thioxo-2-(3-cyclohexeny1)-1H-isoindol-1-one, 3-(2,6-Dioxopiperidin-3-
yl)benzoxazine-2,4-dione, 1-(2,6-Dioxo-3-piperidinylidene)-3-oxoisoindoline, 6-
Thioxo-2-piperidinone, 2,6-Pipelidinedithione, monothiophthalimide,
dithiophthalimide, N-phenethylphthalimid.e, 3-Benzylimino-2-benzy1-2,3-
dihydroisoindo1-1-one, 3-Camphanic amino-2,6-piperdinedione and 3-[2',6'-
piperidinedion-3'-y1]-7-amino-2H-1,3-benzoxazine-2,4(3H)-dione; and a
pharmaceutically acceptable carrier. In more particular embodiments, the
disclosed
compositions are compounded for oral administration, and such oral dosage
forms
can include one or more of any of the disclosed compounds including those
compounds particularly disclosed by their IUPAC names above. Such
pharmaceutical compositions may be used in methods for modulating angiogenesis
or TNF'-a activity in a subject by administering to the subject a
therapeutically
effective amount of the composition.
As is demonstrated in the Examples that follow, thionation of thalidomide
analogs to replace carbonyl groups with thiocarbonyl groups can provide
thalidomide analogs with increased TNF-a activity, increased angiogenic
activity or
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
30
increased anti-angiogenic activity. Thus, although in certain structures the
compounds are shown with carbonyl groups, it is to be understood that
thionated
derivatives of such compounds are also part of the disclosure.
4. Examples
Example 1 - Improved Synthesis of Thalidomide
With reference to Scheme 1 below, t-Butoxycarbamate 2, on reaction with
carbodiimide in THF, gave imide 3. Imide 3 was deprotected with
trifluoroacetic
acid in CH2C12 at room temperature to yield aminoglutarirnide trifluoro
acetate 4.
Without further purification, compound 4 was reacted with phthalic anhydride
in
refluxing THF in the presence of triethylamine to afford thalidomide 1 in the
total
yield of 24% from 2. This procedure is much more practical and efficient than
several prior reported synthetic routes for the preparation of thalidomide.
1H 0 0
0 N¨LICONH2COOH THE 0
2 3
1 cF3c00H
0 0 0
110 N¨Iy\IFI 0 = H2N 0 CF3COOH
0 1 4
Scheme 1
2,6-Dioxo-3-(t-butoxycarbonylamino)piperidine (3) was prepared and
isolated as follows. A solution of N-(t-butoxycarbony1)-L-glutamine (4.92 g)
and
carbonyl diimidazole (1.70 g) in THF (100 mL) was refluxed for 9 h. The
solvent
was removed and the crude product was recrystallized from hot Et0Ac to give
compound 3 (2.04 g, 45%) as white crystals: mp 214-215 C; NMR (DMSO-d6) 5
4.22 (dd, J = 6.2 Hz, J = 11.0 Hz, 1H), 2.77-2.65 (m, 1H), 2,45 (m, 1 H), 1.96-
1.87
(m, 2H), 1.40 (s, 9H); MS (Cl/C114) 227 [M-1]-1-.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
31
2,6-Dioxo-3-aminopiperidine trifluoroacetate (4) was prepared and isolated
as follows. Compound 3 (59 mg) was suspended in CH2C12 (5 mL). CF3COOH (0.5
mL) was added. The reaction solution was stirred at room temperature for 4 h.
The
solvent was removed to give 4 (62 mg, 99%): IFINMR (DMSO-d6) 8 11.42 (s, 1H),
8.70 (br, 2H), 4.31 (dd, J =5.4 Hz, J = 13 Hz), 2.88-2.72 (m, 2H), 2.25-2.09
(m, 2H).
Thalidomide (1) was prepared and isolated as follows. A mixture of 4,
phthalic anhydride and Et3N in THF was refluxed for two days. The reaction
mixture was concentrated and purification by column chromatography (eluent
CH2C12/Et0Ac=6:1) gave thalidomide (104 mg, 54%) as white crystals.
Example 2 - Synthesis of Aromatic Thalidomide Analogs
With reference to Scheme 2 below, dimethylether 5 was obtained by
condensation of aminopyridine with phthalic anhydride in refluxing AcOH in the
presence of sodium acetate. On standing with HBr in glacial AcOH solution (30
%)
at room temperature for 18 h, selective ether cleavage of 5 was accomplished
to give
compound 6. The structure of compound 6 was determined by mass spectroscopy,
1D NMR and 2D NMR. The molecular ion for compound 6 is 270 amu,
demonstrating that only one methyl ether was cleaved. 2D NOESY showed that
protons on the methoxy group correlated with H-5, indicating that the 2-
methoxy
was selectively cleaved and that the 6-methoxy remained. When the reaction
temperature elevated to 70 C, both methyl ethers were cleaved with HBr/HOAc
solution (30%) to give diol 7.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
32
O , ,x.I\J H2 0 Me0 ¨N
I HCI HOAc
0 -E. , 101 N--)\---,?-0Me
Mei N OMe Na0Ac
O 05
0 HO
N OMeHBr
= Me0
0
--N
0 HO
O
= N OH HBr
7
Scheme 2
1,3-Dioxo-2-(2,6-dimethoxypyridin-3-y1)-isoindoline (5) was prepared and
isolated as follows. A mixture of phthalic anhydride (0.89g, 6 mmol), 3-amino-
2,6-
dimethoxypyridine monohydrochloride (95%, 1 g, 5 mmol) and sodium acetate
(0.49 g, 6 mmol) in glacial acetic acid (50 ml) was refluxed for 3 h. The
solvent was
removed under vacuum. The residue was dissolved in dichloromethane (200 ml)
and washed with water (100 mlx3), dried over Na2SO4 and concentrated to give
the
crude product. The crude product was recrystallized with ethyl acetate to give
5
(1.345 g, 90%) as a pale pink crystals: mp 182-183 C; 111NMR (CDC13) 8 7.96-
7.90
(m, 2H), 7.80-7.76 (m, 2H), 7.44 (d, J = 8.1 Hz, 1H), 6.42 (d, J = 8.1 Hz, 1H,
3.95
(s, 3 H), 3.91 (s, 3 H); 13C NMR (DMSO-d6) 8 166.5, 160.6, 156.1, 140.1,
132.8,
129.4, 121.4, 104.6, 99.3, 51.7, 51.5; MS (Cl/CH4) 285 [M+1]+. Anal. Calcd for
C15H12N204: C, 63.38; H, 4.25; N, 9.85. Found: C, 63.57; H, 4.18; N, 9.65.
1,3-Dioxo-2-(2-hydroxy-6-methoxypyridin-3-y1)-isoindoline hydrobromide
(6) was prepared and isolated as follows. To a flask were added 2,6-dimethoxy-
3-
phthalimidopyridine (155 mg, 0.546 mmol) and hydrogen bromide solution in
acetic
acid (30%, 6 ml). The mixture was stirred at room temperature under N2 for 18
h.
Dry ether was added slowly until the solution became cloudy. White crystals
were
precipitated, filtered and washed with ether and ethyl acetate to afford 6
(127 mg,
67%) as white powdery crystals: mp 250 C; 1H NAIR (DMSO-d6) 6 7.97-7.94 (m,
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
33
2H), 7.91-7.88 (m, 2H), 7.64 (d, J = 8.2 Hz, 1H), 6.25 (d, J = 8.2 Hz, 1H),
3.86 (s,
3H); 13C NMR (DMSO-d6) 8 167.5, 162.1, 159.1 , 142.8, 135.4, 132.1, 123.7,
108.2,
96.4, 54.8; MS (Cl/CE) 270 [Mr.
1,3-Dioxo-2-(2,6-dihydroxypyridin-3-y1)-isoindoline hydrobromide (7) was
prepared and isolated as follows. To a flask were added 2,6-dimethoxy-3-
phthalimidopyridine (150 mg, 0.528 mmol) and hydrogen bromide solution in
acetic
acid (30%, 6 ml). The mixture was stirred at an 70 C oil bath under N2 for 54
h.
The mixture was cooled to room temperature, dry ether was added, and the
supernatant liquid was decanted. Then ethyl acetate was added, solid
precipitated,
filtered and washed with ethyl acetate to afford 7 (126 mg, 71%) as a white
solid: 1H
NMR (CD30D) 8 7.83-7.77 (m, 4H), 6.37 (d, J = 8.1 Hz, 111), 6.37 (d, J = 8.1
Hz,
1H); MS (Cl/CH4) 256 [M]+; HRMS (DEI) m/z calcd for C13H8N204 256.0484,
found 256.0483.
Example 3¨ Synthesis of N-Substituted Thalidomide Analogs
With reference to Scheme 3 below, a mixture of N-phthaloyl-DL-glutamic
anhydride and phenethylamine was heated in a 177 C oil bath. The reaction
mixture
was purified by chromatography on a silica gel column to afford N- =
phenethylthalidomide (8) and N-phenethylphthalimide (9).
0 o 0
4.
ioPhenethylamine
= 0 0= 0
Scheme 3
1,3-Dioxo-2-(1-phenethy1-2,6-dioxopiperidin-3-yl)isoindoline (8) was
specifically prepared and isolated as follows. A mixture of N-phthaloyl-DL-
glutamic anhydride (300 mg, 1.13 mmol) and phenethylamine (139 mg, 1.13 mmol)
was stirred in a 177 C oil bath for two hours. The reaction mixture was cooled
down and purified by column chromatography, first using petroleum
ether/dichloromethane (1:5) as an eluent to afford N-phenethyl phthalimide as
a pale
yellow solid [1H NMR (CDC13) 6 7.78-7.77 (m, 2H), 7.65-7.62 (m 2 H), 7.22-7.16
CA 02538864 2012-06-11
63198-1511
34
(m, 5 H), 3.83 (t, 2H), 2.92 (t, 2 H), and then using dichloromethane as an
eluent to
afford N-phenethyl thalidomide as a syrup that was then recrystallized from
ether to
provide white crystals [(139 mg, 34%): mp 122-123 C; 1H NMR (CDC13) 8 7.84-
7.81 (dd, J =3.1 Hz, 1= 5.4 Hz, 211), 7.72-7.69 (dd, J = 3.1 Hz, J = 5.4 Hz, 2
H),
7.20-7.14 (m, 5 H), 4.89 (dd, J = 5.4 Hz, J = 12.5 Hz, 1 H), 4.01-3.92 (m, 2
H), 2.90-
2.63 (m, 5 H), 2.06-2.02 (m, 1 H); Anal. Calcd for C21H15N204: C, 69.60; H,
5.01;
N, 7.73. Found: C, 69.40; H, 5.13; N, 7.74].
Example 4¨ Synthesis of Azathalidomides
With reference to Scheme 4 below, azathalidomide was prepared from
aminoglutarimide and commercial pyridine-3,4-dicarboxylic anhydride. Cbz-
aminoglutarimide was deprotected by hydrogenolysis with catalyst palladium
hydroxide on carbon (10%) to form aminoglutarimide. Pyridine-3,4-dicarboxyic
anhydride was refluxed with aminoglutarimide in the presence of triethylamine
to
yield azathalidomide 11 in the total yield of 17% from Cbz-aminoglutarimide.
I L' 0 H2N 0 0 ¨ 0 0 NH
0 Scheme 4 0 11
1,3-Dioxo-2-(2,6-dioxopiperidin-3-y1)-5-azaisoindoline (11) was prepared
specifically as follows. A mixture of Cbz-aminoglutarimide (302 mg) and
palladium hydroxide on carbon (20%) in 2-propanol (20 ml) was stirred under H2
for
one day. The reaction mixture was filtered through celite"and washed with 2-
propanol and methanol. The combined filtrate was concentrated to afford crude
3-
amino-1,6-dioxopiperidine as syrup. To the flask containing 3-amino-1,6-
dioxopiperidine was added 3,4-pyridinedicarboxylic anhydride (205 mg),
triethylamine (0.16 ml) and THF (10 ml). The mixture was refluxed for one and
a
half days. The solvent was removed under vacuum. The residue was purified by
column chromatography using CH2C12:Me0H (10:1) as eluent to afford
azathalidomide (52 mg) in the yield of 17% from Cbz-aminoglutarimide as a pale
purple solid: mp 233-235 C, 1H (DMSO) 611.18 (s, 111), 9.21 (s, 111), 9.17
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
35
(d, 3 = 4.8 Hz, 1 H), 7.98 (d, 3= 4.8 Hz, 1 H), 5.23 (dd, J = 5.4 Hz, J = 12.8
Hz, 1
H), 2.96-2.85 (m, 2 H), 2.60-2.51 (m, 1 H), 2.12-2.07 (m, 1 H); MS (Cl/CH4)
m/z
259 [Mr; Anal. Calcd for C12H9N204: C, 55.60; H, 3.50; N, 16.21. Found: C,
55.36;
H, 3.44; N, 15.94.
Example 5¨ Synthesis of Acetoxythalidomide Analogs
0 0 00
0 Ac20 0
OH 0 Na0Ac =Ac 0 fisAc0 0
Scheme 5
With reference to scheme 5 above, acetoxythalidomide was prepared and
isolated as follows. First, 3-Acetoxyphathalic anhydride was prepared by
refluxing
a mixture of 3-hydroxyphthalic anhydride (150 mg), acetic anhydride (2 mL),
and
Na0Ac (150 mg) for 8 h. The reaction mixture was filtered. The filtrate was
concentrated and washed with dry ether to give a pale yellow solid (127 mg,
68%).
1H NMR (DMSO) 8 8.25 (d, 3 = 7.9 Hz, 111), 8.18 (dd, J = 0.9 Hz, J = 7.5 Hz,
1H),
7.97 (dd, 3 = 0.9 Hz, J = 7.9 Hz, 113), 2.59 (s, 3H).
1,3-Dioxo-2-(2,6-dioxopiperidin-3-y1)-4-acetoxyisoindoline was prepared
and isolated as follows. A mixture of 3-acetoxyphthalic anhydride (40 mg),
aminoglutarimide trifluoroacetate (47 mg), and Na0Ac (32 mg) in acetic acid (2
mL) was refluxed for 5 h. The solvent was evaporated, water (10 mL) was added,
and the resulting solution was stirred for several minutes. The solid was
filtered out
and recrystallized from ethyl acetate to give 1,3-dioxo-2-(2,6-dioxopiperidin-
3-y1)-
4-acetoxyisoindoline as pale yellow crystals (35 mg, 66%): 1H NMR (DMSO)
11.16 (s, 1H), 11.07 (s, 1H), 7.64 (t, J = 7.2 Hz, 1H), 7.22-7.31 (m, 2H),
5.05 (dd, J
= 5.4 Hz, 3 = 12.5 Hz, 1H), 2.87-2.92 (m, 2H), 2.48 (s, 3H), 2.08-2.00 (m,
2H).
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
36
Example 6¨ Synthesis of Benzothalidomides
With reference to Scheme 6 below, 1,8-Naphthalic anhydride on heating
with amine 4 in the presence of tfiethylamine in THF gave 12. Naphthalene-2,3-
dicarboxylic acid was converted to the anhydride 13 which was reacted with
aminoglutarimide trifluoroacetate 4 to afford benzothalidomide 14. Spectral
data,
including mass spectra and NMR, as well as combustion analyses were in accord
with the structures assigned to these products.
0 0
+ H2N_t 0 cH = N 0
0 4 0
as: COOH Ac20 .0 0 0 00 12 0 0
13 0 140
Scheme 6
Specifically, N-(2,6-dioxopiperidin-3-y1)-1,8-naphthalimide (12) was
prepared and isolated as follows. A mixture of amine 4 (0.877 mmol), 1,8-
naphthalic anhydride (174 mg, 0.879) and triethylamine (1.22 ml) in THF (10
ml)
was refluxed for 20 h. The solvent was removed and the residue was suspended
in
acetic anhydride and refluxed for 20 minutes. Ethanol (5 ml) was added at 80 C
and
stirred for 30 mm. On cooling the product was collected by filtration, and
washed
with Et0Ac to give compound 12 (227 mg, 84%) as a pale green solid: mp > 300
C;
1H NMR (DMSO-d6) 8 11.03 (s, 1H), 8.61-8.47 (m, 4H), 7.92 (dd, J = 7.3 Hz, I =
13.5 Hz, 2H), 5.85 (dd, J = 5.4 Hz, J = 11.3 Hz, 1H), 3.01-2.88 (m, 1H), 2.73-
2.61
(m, 2H), 2.08-1.99 (m, 1H). MS (DEI) m/z 309 [M+11+; HRMS (DEI) m/z calcd for
C171-113N204 309.0875, found 309.0874; Anal. Calcd for C17H12N204: C, 66.23;
H,
3.92; N, 9.09. Found: C, 65.97; H, 3.99; N, 8.91.
N-(2,6-dioxopiperidin-3-y1)-2,3-naphthalenedicarboxamide (14) was
prepared and isolated as follows. A mixture of 2,3-naphthalenedicarboxylic
acid
(199 mg, o.875 mmol) and acetic anhydride (2 mL) was refluxed for 30 min. The
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
37
reaction mixture was cooled down, and the solid was collected by filter to
afford
anhydride 13 (0.133 g, 77%) as a white solid. To a solution of
aminoglutarimide
trifluoroacetate (163 mg) and triethylamine (1 mL) in THF (10 mL) was added
anhydride 13 (133 mg). The mixture was refluxed for 16 h. The solvent was
removed under vacuum, and the residue was dissolved in Et0Ac, washed with
saturated aqueous NaHCO3 solution and 1120, dried and concentrated. The
residue
was purified by flash chromatography to give compound 14 as a white solid (146
mg, 70%). mp > 300 C; 111 NMR (DMSO-d6) 8 11.3 (s, 1H), 8.60 (s, 2H), 8.30
(dd,
J = 3.3 Hz, J = 6.1 Hz, 2H), 7.82 (dd, I = 3.2 Hz, J = 6.2 Hz, 2H), 5.24 (dd,
J = 5.6
Hz, J = 13.0 Hz, 1H), 2.99-2.86 (m, 2H), 2.66-2.57 (m, 2H), 2.12-1.99 (m, 1H).
MS
(DEI) naJz 308 [M]; HRMS (DEI) miz calcd for C171112N204 308.0797, found
308.0798; Anal. Calcd for C17H12N204Ø25H20: C, 65.28; H, 4.03; N, 8.96
Found:
C, 65.42; H, 3.93; N, 8.94.
Example 7- Synthesis of Sulfur Analogs of Thalidomide
With reference to Scheme 7 below, reaction of thalidomide 1 with
Lawesson's reagent, when stirred in benzene at 80 C for 48 h, yielded
thionamide
15 in a yield of 38%. In addition to monothiothalidomide, a trace of
dithionimide 16
(1.6%) was also obtained. However, for the preparation of dithionimide, the
yield
proved to be very low (less than 2%) when the reaction of monothiothalidomide
with Lawesson's reagent was performed between 80 C to 120 C. The situation
changed greatly when organic base was added to the reaction mixture. Thus,
thionation of monothiothalidomide 15 with Lawesson's reagent in toluene was
carried out at 110 C in the presence of pyridine to give dithionimide 16 (45%)
and
dithionimide 17 (31%). The structures of these sulfur-substituted thalidomides
were
identified by mass spectra, 1DNMR and 2DNMR. Thalidomide was heated with
Lawesson's reagent at 110 C in the presence of morpholine to afford
dithionimide
16 and trithionimide 18.
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
38
40 N_ZN_/Lo Lawesson's Reagent 80C, 2
days
io . 0 S H
S
0
=
1
15
16
0 0 Lawesson's Reagent =s io
S 0
0 s NH
0 15 s O Pyridine
0 17
0 16
0 0
0 S
S s
= 0 Nti=JLFI 0 Lawesson's Reagent ao NZI\JFI s
morpholine =
0
5
1
16
18
Scheme 7
1,3-Dioxo-2-(2-oxo-6-thioxopiperidin-3-ypisoindoline (15) was synthesized
and isolated as follows. A mixture of thalidomide (170 mg, 0.658 mmol) and
Lawesson's reagent (293 mg, 0.724 mmol) in benzene (50 ml) was stirred in a 80
C
oil bath for 2 days. The solvent was removed under vacuum. The residue was
purified by column chromatography using CH2C12/petroluem ether (5:1) as eluent
to
afford compound 16 (3 mg, 1.6%) as a red solid and then, using CH2C12 as
eluent, to
afford compound 15 (68 mg, 38%) as a yellow solid: mp 225-226 C; 1H NMR
(DMSO-d6) 5 12.83 (s, 111), 8.00-7.92 (m, 411), 5.32 (dd, J = 5.6 Hz, J = 12.9
Hz,
111), 3.28-3.25 (m, 1H), 2.60-2.54 (m, 2H), 2.17-2.10 (m, 1H); 13C NMR (DMSO-
d6) 5 208.7(C-6'), 165.3(C-2'), 165.2(C-1 & C-3), 133.1(C-5 & C-6), 129.3 (C-
3a,
C-7a), 121.7 (C-4 & C-7), 46.9 (C-3'), 38.9 (C-5'), 21.79 (C-4'); MS (Cl/CHO
m/z
274 [A]; Anal. Calcd for Cl3H10N203S: C, 56.92; H, 3.67; N, 10.21 Found: C,
56.89; H, 3.78; N, 10.15.
1-Thioxo-3-oxo-2-(2-oxo-6-thioxopiperidin-3-yl)isoindoline (16) and 1,3-
dioxo-2-(2,6-dithioxopiperidin-3-ypisoindoline (17) were synthesized as
follows. A
mixture of 15 (146 mg, 0.533 mmol), Lawesson's reagent (108 mg, 0.267 mmol)
and pyridine (21 pil) in toluene was stirred at 110 C under an atmosphere of
N2 for
12 h. Thereafter, more Lawesson's Reagent (108 mg, 0.267 mmol) and pyridine
(21
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
39
p1) were added. The reaction mixture was stirred for a further 12 h. The
solvent
was removed under vacuum and the residue was purified by column
chromatography (eluent CH2C12/petroleurn ether = 2:1, 10:1, then CH2C12/Et0Ac -
-
10:1) to afford 16 (30 mg, 45%) and 17 (21 mg, 31.5%). Starting material 15
(83
mg) was also recovered.
Compound 16: (yellow solid): mp 263-265 C; 1H NMR (CDC13) 8 7.78-7.74
(m, 2 H), 7.66-7.63 (m, 2 H), 5.00 (dd, J = 4.9 Hz, 11.9 Hz, 1 H), 3.43-3.35
(m, 1
H), 2.95-2.84 (m, 2 H), 2.08-2.06 (m, 1 H); MS (DEI) m/z 290 [M]+; HRMS (DEI)
m/z calcd for C13H10N202S2 290.0184, found 290.0185; Anal. Calcd for
C13H10N202S2: C, 53.77; H, 3.47; N, 9.65 Found: C, 53.38; H, 3.29; N, 9.50.
Compound 17: (red solid): mp 240-242 C; 1H NMR (CDC13) 8 9.44 (s, 1 H),
8.05-8.02 (m, 1 H), 7.86-7.76 (m, 3 H), 5.75-5.64 (m, 1 H), 3.57-3.52 (m, 1
H),
3.09-2.99 (m, 2 H), 2.19- 2.12 (m, 1 H). 13C NMR (DMS0): 208.16, 207.98,
166.10,
165.39, 134.32, 133.11, 132.42, 124.30, 122.15, 121.11, 49.64, 21.29; MS(DEI)
m/z
291 [M+1r; HRMS (DEI) m/z calcd for C13H11N202S2 291.0262, found 291.0264;
Anal. Calcd for C13H10N202S2Ø5H20: C, 52.15; H, 3.70; N, 9.36 Found: C,
52.25;
H, 3.44; N, 9.07.
1-Thioxo-3-oxo-2-(2,6-dithioxopiperidin-3-yl)isoindoline (18) was prepared
and isolated as follows. A mixture of thalidomide (100 mg), Lawesson's reagent
(157 mg) and morpholine (35 p.1) in toluene (10 mL) was stirred at 105 C under
the
atmosphere of N2 for 24 h. The solvent was removed under vacuum and the
residue
was purified by column chromatography, using CH2C12:petroleum ether (1:1) as
eluent, to afford compound 18 (13 mg, 11%) as red crystals: mp 244 C; 1H NMR
(CDC13) 8 10.81 (s, 1H), 8.05-8.01 (m, 1H), 7.91-7.75 (m, 3H), 5.92 (m, 1H),
3.57-
3.52 (m, 1H), 3.13-2.97 (m, 2H), 2.18-2.15 (m, 1H); MS(DEI) m/z 306 [M]+; HRMS
(DE1) m/z calcd for C13H10N20S3 305.9955, found 305.9951; Anal. Calcd for
Ci3H10N20S2-0.5H20: C, 49.49; H, 3.51; N, 8.88 Found: C, 49.85; H, 3.24; N,
8.88.
Then, CH2C12 was used as eluent to provide compound 16 (31 mg, 28%) as yellow
crystals.
CA 02538864 2006-03-09
WO 2005/028436
PCT/US2004/030506
40
Example 8 - Synthesis of Benzoxazine-2,4-diones
With reference to Scheme 8 below, salicylic acid was treated with ethyl
chloroformate, and then this reaction mixture was evaporated at reduced
pressure to
remove any unreacted ethyl chloroformate. Stirring the resulting residue with
amine
in the presence of triethylamine afforded substituted benzoxazine-2,4-diones
0
AN OH C2H5OCOCI 1/ 1
2 -tP NH 60C2F15 H N = y 0
COOH COCOC2H5
NH
0 0
0
19 20
Scheme 8
3-(2,6-Dioxopiperidin-3-yl)benzoxazine-2,4-dione (20) was prepared and
isolated as follows. To a cold ice/salt solution of salicylic acid (100 mg)
and
triethylamine (303 ml) in chloroform (10 mL) was added ethyl chloroformate
(157
ml). The reaction mixture was allowed to warm to room temperature, and,
thereafter, stirring was continued for 3h. The solvent was removed under
vacuum to
give crude 19. Without further purification, crude compound 19 was dissolved
in
CHC13 and cooled with ice. To the ice cold solution was added amine (95 mg).
The
reaction mixture was allowed to warm to ambient temperature and stirred at
room
temperature overnight. The white solid precipitated, collected by filtration
and
washed with chloroform to give compound 20 (79 mg, 74%) as a white crystals:
mp
264 C; 11-1NMR (DMSO-d6) 8 11.18 (s, 1H), 8.07-7.85 (m, 2H), 7.50 (d, J = 8.5
Hz), 5.78-5.75 (m, 0.6H), 5.49-5.47 (m, 0.4H), 2.90-2.87 (m, 1H), 2.05 (m,
1H); 1.3C
NMR (DMSO-d6) 8 173.0 (0.6C), 172.9 (0.4C), 169.9 (0.6C), 169.6 (0.4C), 160.8
(0.6C), 159.8 (0.4C), 152.5 (1C), 148.4 (0.4C), 146.5 (0.6C), 137.2 (1C),
128.1
(0.6C), 127.6 (0.4C), 126.1 (1C), 116.8 (1C), 114.5 (0.4C), 113.9 (0.6C), 54.1
(0.4C), 51.4 (0.6C), 31.0 (1C), 21.2 (1C). MS(DEI) m/z 274 [M]; HRMS (DEI) m/z
calcd for C13H10N205 274.0590, found 274.0582; Anal. Calcd for C13H10N205: C,
56.94; H, 3.68; N, 10.22 Found: C, 56.51; H, 3.77; N, 9.95.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
41
Example 9 ¨ Synthesis of 1-( 2,6-Dioxo-3-piperidinylidene)-3-oxoisoindoline
With reference to Scheme 9 below, monothiophthalimide (21) was stirred
with 3-bromoglutarimide (22) in the presence of Na2CO3 in an Eschenmoser
coupling reaction. Thus, compound 23 was formed by alkylation of
monothiophthalimide with 3-bromoglutarimide, followed by elimination of
sulfur.
0
0 Na2CO3 NH
1101 NH + Br ¨,O ¨ / 0
0 22 1. NH
21 0
23
Scheme 9
1-( 2,6-Dioxo-3-piperidinylidene)-3-oxoisoindoline (23) was specifically
prepared and isolated as follows. A mixture of 21 (16 mg, 0.1 mmol), 22 (19
mg,
0.1 mmol), and potassium carbonate (100 mg) in anhydrous THF was refluxed for
7
h. Thin-layer chromatography (TLC) showed that the starting materials had
disappeared. Ethyl acetate (20 ml) and water (10 ml) were added. The organic
layer
was separated, dried over Na2SO4 and concentrated under vacuum. The residue
was
purified by chromatography using petroleum ether/ethyl acetate (first 2:1 then
1:2)
to give 23 (14 mg, 58%) as yellow crystals: mp 295 C; 11INMR (DMSO-d6): 11.05
(s, 1 H), 10.29 (s, 1 H), 8.13 (d, J = 7.6 Hz, 1 ,H), 7.89 (d, J = 7.2 Hz, 1
H), 7.80 (m,
1 H), 7.73 (m, 1 H), 3.20 (t, J = 7.0 Hz, 2 H), 2.67 (t, J = 7.0 Hz, 2 H). 13C
NMR
(DMSO-d6): 172.6, 169.0, 167.3, 142.7, 136.1, 134.3, 131.7, 130.1, 126.4,
124.1,
104.6, 21.2, 11.7. MS(DEI) m/z 242 [M]+; HRMS (DEI) m/z calcd for C13H10N203
242.0691, found 242.0687.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
42
Example 10¨ Salicylamide Analogs
Reaction of commercial acetylsalicyloyl with amino glutarimide
trifluoroacetate was carried out to give acetylsalicylamide 24 according to
Scheme
below.
0
0
()CC H3
0&H3,H 0
C Ntti
CC I
I I
o 0
24
Scheme 10
More specifically, 2-acetoxy-N-(2,6-dioxopiperidin-3-yl)benzamide (24) was
prepared as follows. To an ice cold solution of acetylsalicyloylchloride (252
mg)
and triethylamine (0.58 mL) in chloroform (30 mL) was added 3-aminoglutaride
trifluoroacetate (207 mg). The reaction temperature was allowed to warm to
room
temperature and stirring was continued overnight. The solvent was removed and
recrystallization from ethyl acetate gave compound 24 as white crystals (0.36
g,
98%): 111 NMR (DMSO-d6) 8 11.00 (s, 1H), 8.73 (d, J = 8.3 Hz, 1H), 7.81 (dd, J
=
1.6 Hz, J = 7.7 Hz, 1H), 7.72 (m, 1H), 7.54 (m, 1H), 7.38 (dd, J = 0.9 Hz, J =
8.1 Hz,
1H), 4.95-4.82 (m, 1H), 2.96-2.90 (m, 1H), 2.43 (s, 3H), 2.18-2.15 (m, 2H).
Example 11 ¨Synthesis of Thiothalidomides and Determination of Their TNF-ct
Inhibitory Activity
A series of thiothalidomides and analogs were designed to explore their action
on
inhibition of TNF-a. Monothiothalidomide 205 (same as compound 15 in Example
7)
was prepared as shown in Scheme 11. tert-Butoxycarbonyl-L-glutamine 202 was
refluxed with carbonyl diimidazole (CDI) in THF, and cyclized to afford imide
203
(Muller et al., "Amino-substituted thalidomide analogs: potent inhibitors of
TNF-a
production," Bioorg. Med. Chem, Lett. 9, 1625-1630, 1999).
Imide 203 then was treated with trifluoroacetic acid in CH2C12 to remove the
protective group to generate aminoglutarimide trifluoroacetate 204. Without
further
purification, compound 204 was reacted with phthalic anhydride in refluxing
THF in
CA 02538864 2012-06-11
63198-1511
43
the presence of triethylamine to produce thalidomide 201 (same as compound 1
in
Example 7) in the total yield of 31% from compound 202. Thalidomide 201 was
thionated with Lawesson's reagent (LR, Cava et al., "Thionation reaction of
Lawesson's Reagents," Tetrahedron, 41, 5061-5087, 1985)
to generate a single new product that had a structure
identified as 6'-thiothalidomide 205 by mass spectrometry and 1D & 2D nuclear
magnetic resonance spectroscopy. The position of the thiocarbonyl group was
established from the heteronuclear multiple bond correlation (HMBC) cross peak
of H-
5'/C-6'.
Boc¨N 0 a
B oc¨N 0 _/0 F1
C F3C0 2 H3 N 0 0
202 CON H2
203
204 c
401 0 o
101 N 0 o 0
205
0201
Scheme 11: Reagents: (a) CDI/THF; (b) CF3COOH/CH2C12; (c) phthalic
anhydride, Et3N/THF; (d) Lawesson's reagent/toluene.
The synthesis of 3-thiothalidomide 212 is shown in Scheme 12 below. N-
Phthaloyl-L-glutamic acid 206 was esterified to afford diester 207. Compound
207 was
thionated with LR at 110 C to give compound 208 as a major product.
Concurrently,
compound 209 was separated as a minor product by chromatography.
3-thiothalidomide, 212, could not be prepared through the cyclization of
compound 208 with ammonia or amine as ammonia reacts with the thioamide;
reaction
of compound 208 with benzylamine produced the unexpected compound 210. In an
alternative approach, compound 208 was hydrolyzed under acidic conditions to
give
diacid 211. Compound 211 was then reacted with trifiuoroacetamide to generate
3-
thiothalidomide 212 in the presence of 1-hydroxybenzotriazole (HOBt) and 1-[3-
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
44
(dimethylamino)propy1]-3-ethylcarbodiimide hydrochloride (EDCI, Flaih et al.,
"An
expeditious synthesis of cyclic imides," Tetrahedron Lett. 40, 3697-3698,
1999).
0 0 s 0 s 0
140 N RcH3 101 N FI3 + N RCH3
0 0 0 0 0
207 0 0H3e 1208 0 CH3 209 0 CH3
S S
I% 01
4o d 401 N
=N
0 0 0H 0 41
212 211 0 210
Scheme 12: Reagents: (a) Lawesson's reagent/toluene; (b) Benzylamine; (c)
HC1/HOAc; (d) F3CCONH2, HOBt, EDCI, Et3N/CH2C12.
In the synthesis of dithiothalidomide, one method involved the reaction of
monothiothalidomide with LR at reflux in toluene. Under such conditions, 2',6'-
dithiothalidomide was obtained in a yield of less than 2% (Scheme 13a). The
yield was
so low that improvement was desirable, and was undertaken by modifying the
reaction
conditions. It is believed that the mechanism underlying the reaction between
LR and a
carbonyl moiety is that a highly reactive dithiophosphine ylide 214, rather
than LR
itself, likely is the active thionating agent (Scheme 4, Cava et al.,
"Thionation reaction
of Lawesson's Reagents," Tetrahedron, 41, 5061-5087, 1985, the entirety of
which is
incorporated herein by reference). The Lewis base may be able to increase the
reactivity of LR as the base may drive the unfavorable equilibrium and elevate
the
concentration of the ylide 214. When pyridine was used as a catalyst for
thionation,
monothiothalidomide 205 was thionated with LR to produce two
dithiothalidomides,
213 (same as compound 16 in Example 7) and 215 (same as compound 17 in Example
7), in yields of 45% and 31%, respectively (Scheme 13 b,c). Dithiothalidomide
213
was further thionated with LR in the presence of the stronger base,
morpholine, to give
trithiothalidomide 216 (same as compound 18 in Example 7) in a yield of 65%.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
45
= 0 = s
a
1110 N S 1101 E/1 s
0 213 1.6%
205
S o
213
45% I01
31%
0
215
S s
S
65%
216
Scheme 13: Reagents: (a) Lawesson's reagent/toluene; (b) Lawesson's reagent,
pyridine/toluene; (c) Lawesson's reagent, morpholine/toluene.
S s
Me0 V )D ome Me0 P¨s-
\
s s
214
Scheme 14. The mechanism of catalysis for Lawesson's reagent.
Glutarimide 217 was thionated with LR in THF at room temperature to afford
compound 218 as a major product. Glutarimide 217 also was refluxed with LR in
toluene to produce dithioglutarimide 219 (Scheme 15). Reaction of potassium
phthalimide with 3-bromocyclohexene in a Gabriel reaction gave compound 221.
Thereafter, thionation of compound 221 with LR afforded compounds 222 and 223
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
46
(Scheme 16). Compounds 224 and 225 were prepared in a similar procedure to
that
used in the preparation of compounds 222 and 223.
rs-.1 S N 0
ONO * 218
217
219
Scheme 15. Reagents: (a) Lawesson's reagent/THF, room temperature; (b)
Lawesson's reagent, reflmdtoluene
0 0
= N-c)= _o +
0 0 0
220 221 222 223
Scheme 16. Reagents: (a) 3-bromocyclohexene/DMF; (b) Lawesson's
reagent/toluene.
CA 02538864 2012-06-11
63198-1511
47
The structures of the thiothalidomide compounds of this Example are
summarized below.
Ra Rb
Ra 0
0
011
12. 11111 N 1 N
0
Rb
0 Rd=Rd 0\
205: Ra = 0, Rb = 0, Rc= S
208: Ra S, Rb = 0, Rd= Me
212: Ra = S, Rb = 0, Rc= 0
209: Ra = S, Rb = S, Rd=
Me
213: Ra = 0, Rb S, Rc= S
211: Ra = S, Rb = 0, Rd=
H
215: Ra = S, Rb = 0, Rc= S
216:R1=S,Rb=S,Rc=S
Ra
Ra
N--(1) 40 NH
Ra ,v7'
Rb
Rb
218: Ra S, Rb 0
222: Ra = S, Rb = S
224: Ra = Rb = S
219: Ra = S, Rb S
223: Ra = S, Rb = 0
225: Ra = S, Rb = 0
The action of the these thiothalidornide analogs in inhibiting TNF-a
secretion was assessed in human peripheral blood mononuclear cells (PBMC) and
the results are shown in Table 1. Freshly prepared PBMCs were utilized in all
studies. Blood, 40 ml, was drawn from a volunteer, immediately mixed with 50
U/ml Na heparin and was diluted to 50 ml total volume with sterile PBS.
Samples,
20 ml, of this preparation then were layered on 20 ml Ficoll-Paquermand were
centrifuged (800g, 20 min). The Ficoll/serum interface, containing PBMCs, was
collected, diluted to 200 ml with PBS, and then was centrifuged (800g, 15 min)
to
pellet the cells. Thereafter, the recovered pellet was re-suspended in 37 C
tissue
culture medium (RPMI/1 mM Sodium pyruvate/10% heat inactivated FBS/ 2mM
Glutamax) and placed on ice. Recovered cells were counted, pipetted (200 ul of
5 x
105/m1) into 96 well plates, and incubated for an hour (37 C, 5% CO2).
Thereafter,
CA 02538864 2012-06-11
63198-1511
48
appropriate concentrations of test compounds or vehicle (10 ul DMSO) were
added
to duplicate wells. Following a further hour of incubation, a 10 ul sample of
lipopolysaccharide (LPS)(100 ng/ml in supplemented medium) or vehicle was
added
to induce stimulated and unstimulated cells, respectively, and the cells were
incubated overnight. Sixteen hours later, supernatants were collected for
quantification of TNF-a levels by ELISA assay (Pierce-Endogen human TNF-a
mini kit, Rockford, IL) and the use of specific capture and detection
monoclonal
antibodies, M303E and M302B (Pierce-Endogen), respectively. ELISA plates were
read at X:=450 nm and TNF-a levels were determined from a six-point
calibration
curve that was run concurrently with the test samples. The effect of test drug
concentrations on the cellular viability of PBMCs was assessed by MTS assay
TM
(Promega, Madison, WI) of the cells that provided the supernatant samples
assayed
for TNF-a levels, described above. It should be understood that this method
can be
used to test any of the disclosed compounds as a screening assay for readily
determining their TNF-a modulating activity, and for selecting them for use in
the
disclosed method of treating a subject.
WO 2005/028436 CA 02538864 2006-03-09 PCT/US2004/030506
49
Table 1. Inhibition of LPS-induced TNF-a production in PBMC and cell viability
% Inhibition IC50 Cell viability
Compound at 30 p,M ( M) at 30 M at 3 pM at 0.3 p,M
205 31 >30 >100 90 96
208 56 20 93 99 96
209 85 10 , 57 86 89
211 20 >30 86 93 93
212 23 >30 94 100 94
213 52 20 69 87 94
215 61 11 >100 87 94
216 79 6 94 86 90
218 15 >30 >100 84 86
219 75 8 >100 98 99
222 86 15 50 94 96
223 85 16 57 89 99
224 95 3 54 83 83
225 34 >30 >100 94 94
Thalidomide, 201, entirely lacked activity at 30 M. A concentration of 100
M was required for significant activity (IC50 ¨200 M). The
monothiothalidomides,
6`-thiothalidomide 205 and 3-thiothalidomide 212 showed only marginal activity
at 30
pM with 31% and 23% inhibition of TNF-a, secretion, respectively. In contrast,
the
dithiothalidomides, including 2', 6'-dithiothalidomide 213 and 3, 6'-
dithiothalidomide
215, exhibited more potent inhibitory activities with IC50 values of 20 M and
11 M,
respectively. However, assessment of cell viability by MTS assay showed that
213
induced increasing cytotoxicity at higher concentrations. Trithiothalidomide
216
inhibited TNF-a production with an IC50 of 6 !AM, without accompanying
toxicity.
Compared withthalidomide, 201, with an 1050 of ¨200 M for the inhibition of
TNF-a
synthesis, trithiothalidomide 216 is over 30-fold more active. Hence,
successive
replacement of a carbonyl with a thiocarbonyl group led to improved inhibitory
,activity
compared to 201, unassociated with toxicity. In this regard, the synthesized
,
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
50
thiothalidomides possessed TNF-a lowering potency in the following decreasing
order:
trithiothalidomide 216> dithiothalidomide 215 and 213 > monothiothalidomides
205
and 212 > thalidomide, 201.
A comparison of the physical properties of thalidomide, 201, and
thiothalidomides shows that they have similar Van der Waals radii and bond
angles,
although the C=S bond is slightly longer than the C=0 bond. Although not
wishing to
be bound by any particular theory, a possible explanation accounting for the
elevated
potency of the thiothalidomides is that their enhanced lipophilicity and loss
of hydrogen
bond acceptor capability potentially allows the attainment of higher
intracellular drug
levels. Interestingly, compounds 208, 209 and 211 are thio analogs of
hydrolysis
metabolites of thalidomide. Assessment of their TNF-a inhibitory action
determined
that the monothio analog, 208, has an IC50 of 20 piM without toxicity;
demethylation
(211) lowered potency. The dithio analog, 209, proved 2-fold more potent still
than
208, but induced cellular toxicity at lower concentrations. Intriguingly, thio
analogs
222 and 223, with a simplified glutarimide ring, were found to be active TNF-a
inhibitors, albeit with some toxicity at 30 M, with IC50 values (15 },LM and
161.1M
respectively) that were greater than 212 (>301.IM) possessing a normal
glutarimide ring.
In this regard, thalidomide is composed of two distinct moieties: the
glutarimide
and phthalimide rings. Thioglutarimides and thiophthalimides were thus
synthesized
and evaluated to assess the effect of thio-analogs of these two moieties on
TNF-a
levels. Monothioglutarimide 218 minimally inhibited TNF-a secretion at a
concentration of 30 M, however dithioglutarimide 219 exerted a potent
inhibitory
effect with an IC50 of 811M and a lack of toxicity. Surprisingly, such a
simple structure,
dithioglutarimide 219, proved to be 25-fold more active than thalidomide 201.
In
contrast, 2',6'-dithiothalidomide 213, a phthalimido substituted
dithioglutarimide, is less
active than dithioglutarimide 219, and induces toxicity at high concentration.
Monothiophthalimide 225 showed marginal TNF-a activity at a concentration of
30
1.1M without toxicity. Interestingly, however, dithiophthalimide 224 was found
to
possess potent activity with an IC50 of 3 'LIM. Although it was associated
with toxicity
at 30 !AM, its inhibition of TNF-a occurred at an order of magnitude lower
concentration that was well tolerated.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
51
As described, compounds 215, 216 and 219 potently inhibited TNF'-a secretion
without toxicity. As a consequence, additional studies were undertaken to
elucidate the
mechanism underpinning this action. Gene and protein expressions are
controlled at the
level of transcription, post-transcription, RNA stability, and translation
under different
physiological stimuli. Recently, post-transcriptional pathways have been
recognized to
provide a major means of regulating eukaryotic gene expression. In this
regard, TNF-a
and other cytokines and protooncogenes are known to be regulated at the post-
transcriptional level. Multiple proteins, including the four cloned proteins
AUF1, HuR,
TTP and HuD have been shown to bind to a region of the mRNA that contains
adenylate/uridylate (AU)-rich elements (AREs) in the 3'-untranslated region
(UTR).
These proteins mediate RNA turnover and decay, and hence translational
efficiency. .
The stability of TNF-a mRNA is largely regulated at its 3'-UTR, which contains
a well
characterized ARE. Although AREs are found in a number of different cytokine
and
protooncogene RNAs, the pathways by which they induce degradation are highly
specific for a given ARE indicating some cellular specificity. When the AREs
from
different cytokines are complexed with AUF1, different binding affinities are
observed.
Notably, however, the highest affinity for AUF1 is to human and then mouse TNF-
a.
To determine the involvement of the 3'-UTR in the action of the thalidomide
analogs, their ability to inhibit reporter gene activity in cells containing
the TNF-a 3'-
UTR versus a control vector was assessed. The results are shown in FIG. 1.
This cell-
based assay utilized two stably transfected cell lines derived from the mouse
macrophage line, RAW264.7. One line, designated "luciferase only" expressed a
luciferase reporter construct without any UTR sequences. The other line,
designated
"luciferase + TNF-a UTR" expressed a luciferase reporter construct with the
entire 3'-
UTR of human TNF-a inserted directly downstream of the luciferase coding
region.
Compounds were added in a concentration-dependent manner, and at the end of
the
incubation period (16 h, 37 C, 5% CO2) the media was removed, cells were lysed
and
luciferase activity was assayed with Steady-glo luciferase assay reagent
(Promega)
according to the supplier's directions. Background was subtracted and data
from this
assay was expressed as a ratio of the +3'-UTR to ¨3'-UTR (control) values, and
was
expressed as a percent as shown in FIG. 1. In this manner, compounds that show
a
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
52
differential effect on the two cell lines, with and without a 3'-UTR, are
highlighted.
The action of compounds 215, 216 and 219 in cells (mouse macrophage cell line,
RAW264.7 ) possessing a luciferase reporter element plus the 3'-UTR of human
TNF-a
compared to cells lacking the 3'-UTR are shown in FIG. 1. Compounds 215, 216
and
219 exerted differential effect on the two cell lines in a dose-dependent
manner,
consistent with their ability to inhibit TNF'-a production via the 3'-UTR. All
agents
lowered luciferase reporter activity in cells stably expressing the 3'-UTR.
Thalidomide
lacked activity at 501.11\4.
As TNF-a protein levels changed without significant alterations in mRNA
levels (data not shown), protein expression is presumably regulated via
translational
control (at the post-transcriptional level). There is precedence for
translational (protein)
control through either the 3'- or 5'-UTR regions of a number of critical
proteins that are
current drug targets. For example, levels of the beta-amyloid precursor
protein (APP)
that is central to the development of AD can be regulated by either UTR.
Turnover and
translation of APP mRNA is regulated by a 29-nucleotide instability element
within the
3'-UTR, located 200 nucleotides downstream from the stop codon. This 3'-UTR
element acts as an mRNA destabilizer whose function can be inhibited by the
presence
of growth factors. In contrast, different cytokines, including TNF-a, and iron
can up
regulate APP protein synthesis at the level of its 5'-UTR; where,
interestingly, the
anticholinesterase, phenserine, that is currently in clinical trials for AD,
lowers APP
protein levels with concurrent maintenance of mRNA steady-state levels through
translational modification within the same 5'-UTR element. A further example
is that
of the human immunodeficiency virus 1 (HIV-1) Trans-activating transduction
(tat)
protein, which binds trans-activation-responsive region (TAR) RNA. Tat is
brought
into contact with the transcription machinery after binding the TAR element,
which is a
59-residue stem-loop RNA found at the 5' end of all HIV-1 transcripts.
Finally,
thalidomide (201) has been reported to lower cyclooxygenase-2 (Cox-2)
biosynthesis
via its 3'-UTR that appears to likewise contain an ARE that can regulate Cox-2
mRNA
stability. The studies of analogs 215, 216 and 219 confirm regulation of TNF-a
protein
levels by thalidomide (201) via its 3'-UTR, but whether or not the 5'-UTR
contains a
similar element that is accessible to pharmacological manipulation remains to
be
determined, as does action against Cox-2.
CA 02538864 2012-06-11
63198-1511
53
In summary, disclosed thiothalidomide analogs include analogs that are more
potent inhibitors of TNF-a production in LPS-induced human PBMCs than
thalidomide
201. The isosteric replacement of successive carbonyl groups by a thiocarbonyl
leads
to an increasing inhibition with the number of moieties replaced
(trithiothalidomide 216
> dithiothalidomide 215 and 213 > monothiothalidomides 205 and 212 >
thalidomide
201).
TNF-a has been validated as a drug target for two drugs on the market;
RemicadeTm(Cetocor, Malvern, PA; Schering-Plough, Orange, NJ) and
Enbreim(Amgen,
Thousand Oaks, CA; Wyeth-Ayerst, Princeton, NJ). However, both of these drugs
are
large macromolecules and hence require injection. In contrast, the small
molecule
drugs disclosed herein offer a means to potently and safely inhibit TNF-a
without
injection, for example, by oral administration.
Synthesis and Characterization Details
General. Melting points were determined with a Fisher-Johns apparatus and
are uncorrected. H NMR, 13C NMR and 2D NMR were recorded on a Bruker AC-
300 spectrometer. Mass spectra and high resolution mass spectra (HRMS) were
recorded on a VG 7070 mass spectrometer and a Agilent Technologies 5973N GC-
TM
MS (CI). All exact mass measurements show an error of less than 5 ppm.
Elemental
analyses were performed by Atlantic Microlab, Inc., Norcross, GA.
3-(tert-Butoxycarbonylamino)-2,6-piperidinedione (203). A mixture of N-
(tert-butoxycarbony1)-L-glutamine (4.92 g, 20 mmol) and carbonyl diimidazole
(3.24 g,
20 mmol) in THF (100 mL) was refluxed for 16 h. Thereafter, solvent was
removed
and the crude product was recrystallized from hot Et0Ac to give compound 203
(2.04
g, 45%) as white crystals: mp 214-215 C; 1H NMR (DMSO-d6) 6 4.22 (dd, J = 6.2
Hz, J
= 11.0 Hz, 1H), 2.77-2.65 (m, 1H), 2,45 (m, 1 H), 1.96-1.87 (m, 2H), 1.40 (s,
9H); MS
(Cl/CH4) m/z 227 [M-11+.
2-(2-0xo-6-thioxo-3-piperidiny1)-1H-isoindole-1,3(211)-dione (205).
Compound 203 (1.14 g, 5 rnmol) was suspended in CH2C12 (100 mL). To the
mixture
was added CF3COOH (10 mL) and this then was stirred at room temperature for 4
h.
The solvent was evaporated to give crude 204 (1.25 g): 1H NMR (DMSO-d6) 5
11.42 (s,
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
54
111), 8.70 (br, 2H), 4.31 (dd, J =5.4 Hz, J = 13 Hz), 2.88-2.72 (m, 2H), 2.25-
2.09 (m,
2H). A mixture of crude 204 (1.25g) and phthalic anhydride (0.89 g, 6 mmol)
and Et3N
(1.39 ml, 10 mmol) in THF (150 mL) was refluxed for two days. The reaction
mixture
was concentrated and the residue was crystallized from ethyl acetate to give
thalidomide (201) (0.89 g, 69%) as white crystals; mp 276 C (lit.276-279 C). A
mixture of thalidomide 201 (258 mg, 1 mmol) and Lawesson's reagent (222 mg,
0.55
mmol) in toluene (50 ml) was stirred at reflux for 12 h; thereafter, solvent
was removed
under vacuum. The resulting residue was purified by column chromatography
using
CH2C12 as the eluent to afford compound 205 (200 mg, 73%) as a yellow solid:
mp 225-
226 C; 1H NMR (DMSO-d6) 8 12.83 (s, 111, NH), 8.00-7.92 (m, 411, Ph), 5.32
(dd, J =
5.6 Hz, J = 12.9 Hz, 111,11-3'), 3.28-3.25 (m, 2H, H-5'), 2.60-2.54 (m, 1H, 11-
42 2.17-
2.10 (m, 1H, 11-4'); 13C NMR (DMSO-d6) 8 208.7(C-61, 165.3(C-2'), 165.2(C-1 &
C-
3), 133.1(C-5 & C-6), 129.3 (C-3a, C-7a), 121.7 (C-4 & C-7), 46.9 (C-3'), 38.9
(C-5'),
21.79 (C-4'); MS (Cl/C114) nilz 274 (M+); Anal. (C13H10N203S) C, H, N.
Dimethyl 2-(1,3-dihydro-1,3-dioxo-2H-isoindo1-2-y1)-pentanedioate (207).
To a solution of N-phthaloyl-L-glutamic acid (200 mg, 0.72 mmol) in methanol
(10
mL) was added, dropwise, thionyl chloride (1 mL). The reaction mixture was
refluxed
for 6 h. The solvent was removed under reduced pressure, dissolved in ethyl
acetate
(100 mL), and then washed with saturated aqueous Na2CO3 solution (2x30 mL) and
water (2x30 mL). The ethyl acetate layer was dried over Na2SO4 and then
evaporated,
leaving an oil, which upon purification by silica gel chromatography, using
CH2C12:Et0Ac (1:1) as the eluent, gave compound 7 (161 mg, 73%) as an oil; 111
NMR
(CDC13) 8 7.87-7.84 (m, 211), 7.75-7.72 (m 211), 4.91 (dd, J = 5 Hz, J = 9 Hz,
111), 3.73
(s, 3H), 3.62 (s, 3H), 2.67-2.56 (m, 111), 2.51-2.44 (m, 1H), 2.41-2.35 (m,
211).
Dimethyl 2-(1,3-dihydro-1-oxo-3-thioxo-2H-isoindo1-2-y1)-pentanedioate
(208) and Dimethyl 2-(1,3-dihydro-1,3-dithioxo-2H-isoindo1-2-y1)-pentanedioate
(209). A mixture of compound 207 (144 mg, 0.47 mmol) and LR (191 mg, 0.47
mmol)
in toluene was stirred in a 110 C oil bath for 10 h. The solvent was then
evaporated
and the residue was purified by column chromatography, (silica gel) using
CH2C12 as
the eluent, to obtain compound 209 (17 mg, 11%) as a dark red oil. Thereafter,
using
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
55
CH2C12:Et0Ac (10:1) as the eluent the more polar component 208 (105 mg, 70%)
was
obtained as a red oil.
Compound 208: 111 NMR (CDC13) 6 7.98-7.96 (m, 1H), 7.81-7.70 (m, 3H), 5.53
(dd, J = 5.1 Hz, J = 10 Hz, 1H), 3.70 (s, 3H), 3.59 (s, 311), 2.76-2.56 (m,
211), 2.40-2.33
(m, 2H); MS (Cl/CH4) m/z 321 (M+).
Compound 209: 1H NMR (CDC13) 6 7.87-7.84 (m, 2H), 7.73-7.68 (m. 2H), 6.09
(dd, J = 5 Hz, J = 10 Hz, 111), 3.70 (s, 311), 3.58 (s, 3H), 2.81-2.63 (m,
211), 2.40-2.24
(m, 2H); MS (DEI) m/z 337 (M); HRMS (DE1) calcd for C15H15N04S2 337.0442 (M+),
found 337.0449.
2-(1,3-Dihydro-1-oxo-3-thioxo-2H-isoindo1-2-y1)-pentanedioic acid (211).
Compound 208 (350 mg, 1.09 mmol) was stirred with a 1:1 mixture of acetic acid
glacial and conc. HC1 in a 100 C oil bath for 2.5 h. Ethyl acetate (100 mL)
and ice
water (30 mL) were added. The ethyl acetate layer was separated, washed with
ice
water, dried over Na2SO4 and concentrated. The resulting syrup was
crystallized with
ether to afford compound 211 as red crystals (253 mg, 79%); mp 157 C; 111 NMR
(DMSO-d6) 5 8.04-7.96 (m, 1H), 7.91-7.74 (m, 311), 5.43 (dd, J = 5.1 Hz, J =
9.6 Hz,
111), 2.42-2.33 (m, 211), 2.30-2.26 (m, 2H); MS (DEI) m/z 293 (M+); FIRMS
(DEI)
calcd. for Ci3H11NO5S 293.0358 (M+), found 293.0363; Anal. (Ci3Hi1N05S) H, N;
C:
calcd, 53.24; found, 53.88.
2,3-Dihydro-3-thioxo-2-(2,6-dioxo-3-piperidiny1)-1H-isoindo1-1-one (212).
A mixture of compound 208 (81 mg, 0.276 mmol), trifluoroacetamide (57 mg, 0.50
mmol), 1-hydroxybenzotriazole (145 mg, 1.07 mmol), 1-[3-(dimethylamino)propy1]-
3-
ethylcarbodiimide hydrochloride (200 mg, 1.04 mmol) and triethylamine (0.21
mL,
1.51 mmol) in CH2C12 (1.5 mL) was stirred at ambient temperature for 3 days.
Water
(10 mL) and CH2C12 (10 mL) were added. The dichloromethane layer was
separated,
washed with water, dried over Na2SO4 and evaporated under reduced pressure.
Purification by chromatography, with Et0Ac:CH2C12 (1:10) as the eluent, gave
compound 212 (48 mg, 63%) as a red solid: nip 255 C; 1H NMR (CDC13) 6 8.00-
7.98
(m, 1H), 7.80-7.71 (m, 311), 5.63 (br, 1H), 2.98-2.70 (m, 3H), 2.18-2.15 (m,
1H); MS
(Cl/C114) m/z 274 (M); Anal. (C13Hi0N203S) C, H, N.
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
56
2-(2, 6-Dithioxo-3-piperidiny1)-1H-isoindole-1,3(211)-dione (213) and 2,3-
dihydro-3-thioxo-2-(2-oxo-6-thioxo-3-piperidiny1)-1H-isoindo1-1-one (215). The
mixture of 205 (146 mg, 0.533 mmol), LR (108 mg, 0.267 mmol) and pyridine (21
1.11)
in toluene was stirred at 110 C under an atmosphere of N2 for 12 h.
Thereafter,
additional LR (108 mg, 0.267 mmol) and pyridine (21 ul) were added, and the
reaction
mixture was stirred for a further 12 h.. The solvent was removed under vacuum
and the
residue was purified by column chromatography with CH2C12:petroleum ether
(2:1,
10:1) and then CH2C12:Et0Ac (10:1) as eluents to afford 213 (30 mg, 45%), 215
(21
mg, 31.5%) and starting material 205 (83 mg).
Compound 213 (yellow solid): mp 263-265 C; 111 NMR (CDC13) 5 7.78-7.74
(m, 2 H), 7.66-7.63 (m, 2 H), 5.00 (dd, J = 4.9 Hz, 11.9 Hz, 1 H), 3.43-3.35
(m, 1 H),
2.95-2.84 (m, 2 H), 2.08-2.06 (m, 1 H); MS (DEI) m/z 290 (M.); HRMS (DEI)
calcd
for C13H10N202S2 290.0184 (M+), found 290.0185; Anal. (C13H10N202S2) C, H, N.
Compound 215 (red solid): mp 240-242 C; 1H NMR (CDC13) 59.44 (s, 1 H),
8.05-8.02 (m, 1 H), 7.86-7.76 (m, 3 H), 5.75-5.64 (m, 1 H), 3.57-3.52 (m, 1
H), 3.09-
2.99 (m, 2 H), 2.19- 2.12 (in, 1 H). 13C NMR (DMS0): 208.16, 207.98, 166.10,
165.39,
134.32, 133.11, 132.42, 124.30, 122.15, 121.11, 49.64, 21.29; MS (DE1) m/z 291
(MO; FIRMS (DEI) calcd for Ci3H11N202S2 291.0262 (M+), found 291.0264; Anal.
(Ci3Hi0N202S2-0.5H20) C, H, N.
2,3-Dihydro-3-thioxo-2-(2,6-dithioxo-3-piperidiny1)-1H-isoindol-1-one
(216). A mixture of compound 213 (29 mg, 0.1 mmol), LR (22 mg, 0.054 mmol) and
morpholine (9 p1, 0.1 mmol) in toluene (10 mL) was stirred at reflux under an
atmosphere of N2 for 16 h. The solvent was removed under vacuum and the
residue
was purified by column chromatography using CH2C12:petroleum ether (1:1) as
the
eluent to afford compound 216 (20 mg, 65%) as a red solid: mp 244 C; 1H NMR.
(CDC13) 5 10.81 (s, 1H), 8.05-8.01 (m, 1H), 7.91-7.75 (m, 3H), 5.92 (in, 1H),
3.57-3.52
(m, 1H), 3.13-2.97 (m, 2H), 2.18-2.15 (m, 1H); MS(DEI) m/z 306 (M+); HRMS
(DE1)
calcd for Ci3Hi0N,20S3 305.9955 (M+), found 305.9951; Anal.
(Ci3H10N20S3Ø5H20)
C, H, N.
6-Thioxo-2-piperidinone (218). The mixture of glutarimide (0.45 g, 4 mmol)
and LR (0.809 g, 2 mmol) in THF (30 mL) was stirred at room temperature for 2
days.
The solvent was evaporated under vacuum and the residue was purified by column
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
57
chromatography using petroleum ether:Et0Ac (1:1) as the eluent to give
compound 218
as a yellow solid (0.361g, 70%): mp 135 C; 1H NMR. (CDC13) 8 2.96 (t, J = 5.7
Hz, 2
H), 2.58 (t, J = 5.8 Hz, 2 H), 1.96 (m, 2 H); MS (C1/CH4) m/z 129 (M4); Anal.
(C5H7NOS) C, H, N.
2,6-Piperidinedithione (219). A mixture of glutarimide (0.34 g, 3 mmol) and
LR (1.22 g, 3 mmol) in toluene (30 mL) was stirred at reflux for 3 h. The
solvent was
evaporated under vacuum and the residue was purified by column chromatography
using petroleum ether:Et0Ac (20:1) as the eluent to give compound 219 as a
yellow
solid (0.286 g, 66%): mp 103 C; 1H NMR (CDC13) 8 3.02 (t, J = 6.3 Hz, 4H),
1.98 (t, J
= 6.3 Hz, 2H); MS (CUCH4) m/z 145 (M+); Anal. (C5H7NS2) C, H, N.
2-(3-Cyclohexeny1)-1H-isoindole-1,3(211)-dione (221). A mixture of
potassium phthalimide (1.85 g, 3 mmol) and 3-bromocyclohexene (1.79 g, 3 mmol)
in
DMF (15 mL) was stirred in a 100 C oil bath for 12 h. The cooled reaction
mixture
was poured into ice water. The solid was collected by filtration and purified
by flash
chromatography with CH2C12 as the eluent to afford compound 221 (1.6 g, 72%)
as
pink crystals; mp 114 C; 1H NMR (CDC13) 8 7.73-7.69 (m, 2H), 7.62-7.58 (m,
2H),
5.85-5.82 (m, 1H), 5.47-5.44 (m, 1H), 4.80-4.78 (m, 1H), 2.14-2.00 (m, 3H),
1.86-1.78
(m, 2H), 1.64-1.58 (m, 1H).
2-(3-Cyclohexeny1)-1H-isoindo1-1,3(211)-dithione (222) and 2,3-dihydro-3-
thioxo-2-(3-eyelohexeny1)-1H-isoindol-1-one (223). A mixture of compound 221
(68
mg, 0.3 mmol) and LR (121 mg, 0.3 mmol) in toluene was refluxed under N2 for
10 h.
The solvent was removed under vacuum and the residue was purified by column
chromatography using petroleum ether as the eluent to obtain compound 222 (37
mg,
48%) as a dark green solid. Then, using CH2C12:petroleum ether (1:1) as the
eluent, the
more polar component 223 (23 mg, 32%) was obtained as a red solid.
Compound 222: mp 93 C; 1H NMR (CDC13) 67.65-7.60 (m, 2H), 7.49-7.42 (m,
2H), 5.92-5.88 (m, 1H), 5.66-5.63 (m, 1H), 5.47-5.43 (m, 1H), 2.40-2.35 (m,
1H), 1.99-
1.95 (m, 2H), 1.75-1.59 (m, 3H); MS (Cl/CH4) m/z 259 (M+); Anal. (C14H13NS2)
C, H,
N.
Compound 223: mp 67-68 C; 1H NMR (CDC13) 8 7.94- 7.91 (m, 1H), 7.73-7.64
311), 5.92-5.88 (m, 1H), 5.60-5.51 (m, 2H), 2.27-2.10 (m, 311), 1.96-1.76 (m,
2H),
1.81-1.70 (m, 1H); MS (Cl/CH4) m/z 243 (M4); Anal. (Ci4H13N0S) C, H, N.
CA 02538864 2006-03-09
WO 2005/028436 PCT/US2004/030506
58
Dithiophthalimide (225). A mixture of phthalimide ( 436 mg, 3.40 mmol )
and Lawesson's reagent (1.199 g, 3.40 mmol ) in toluene (50 ml) was refluxed (
oil
bath 120 C) under nitrogen for 5 hours. The solvent was removed under vacuum
and the residue was directly chromatographed ( silica gel, petroleum ether:
methylenedichloride / 2: 3 ) to give dithiophthalimide as black red needle
crystals
(240 mg, 39.4%):IHNMR(CDC13) 8 9.80 ( br, 1H), 7.95 ( d, 2H), 7.80 ( d, 2H);
MS
( CI / CH4 ) m/z 179(M).
Example 12-Synthesis and TNF-a Inhibitory Activity of 342',6'-piperidinedion-
3'-
y11-7-amino-2H-1,3-benzoxazine-2,4(3H)-dione
3-[2',6'-piperidinedion-3'-y1]-7-amino-2H-1,3-benzoxazine-2,4(3H)-dione was
prepared as shown below in Scheme 17.
COOH Di-tert-butyl dicarbonateCOOH Ethylchloroformate
BocHN OH BocHN OH
226
0 0t H2N z-1 0 oloH
BocHN 0 =
0 --ckEt H2N 0 0
227 228
Scheme 17
4-(t-Butoxycarbonyl amido)salicylic acid (226) was prepared as follows. To a
mixture of 4-aminosalicylic acid ( 306 mg, 2 mmol ) and di-t-butyl dicarbonate
( 655
mg, 3 mmol ) in H20 was added NaOH ( 2N in H20) at 0 C. This reaction mixture
was allowed to warm to room temperature and then was stirred for 5 hours. 2N
HC1
was added dropwise until the mixture was neutralized. The reaction mixture was
then extracted with Et0Ac, dried and evaporated to give product (336 mg, 66%)
as
a dark gray solid: 111NMR (DMSO-d6) 8 11.50 ( s, 1H), 7.65 ( d, 1H), 6.23 ( d,
1H
), 6.07 ( s, 1H), 1.70 ( s, 9H).
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
59
2-[(Ethoxycarbonypoxy1-4-(t-butoxycarbonyl amido)-benzoic anhydride with
ethyl hydrogencarbonate (227) was prepared as follows. 4-t-Butoxycarbonyl
amidosalicylic acid (226) (101 mg, 0.399 mmol ) in THF ( 10 ml) was cooled
with
dry ice in acetone. Et3N ( 0.166 ml) was added, and then ethyl chloroformate
(108
mg, 1.135 mmol ) was added dropwise over a period of 30 mm. The reaction
mixture was stirred at the same temperature for 5 hours, and then was allowed
to
warm to room temperature. Thereafter, the reaction mixture was stirred
continuously overnight. After evaporation of solvent, the residue was
partitioned
between water and ethyl ether. The ether solution was washed with brine, dried
over
Na2SO4 and evaporation of solvent gave product (111 mg, 70%) as a yellow gum:
111-NMR ( CDC13 ) 8 7.75 ( d, 1H), 6.48 ( d, 1H), 6.38 ( s, 1H), 4.38 (m, 4H),
1.35
(m, 6H).
3-[2',6'-piperidinedion-3'-y1]-7-amino-2H-1,3-benzoxazine-2,4(3H)-dione
(228) was prepared as follows. A mixture of 227 ( 32.8 mg, 0,0826 mmol ),
aminoglutarimide (20 mg, 0.0826 mmol) and Et3N ( 25. 0 mg, 0.248 mmol in 2 ml
THF) was stirred at room temperature overnight. Evaporation of solvent gave a
residue which was stirred with a mixture of Et0Ac and a saturated aqueous
solution
of NaHCO3. The precipitated white solid was collected by filtration as the
product:
114NMR (DMSO-d6) 8 11.3 (br, 1H), 7.85 ( d, 1H), 6.80 ( d, 1H), 6.60 ( s, 1H),
3.15 ( t, 2H ), 2.15 ( t, 2H ).
Evaluation of compound 228 in the TNF-a assay described above in Example
11 showed that it possessed potent inhibitory action on TNF-a, having an EC50
of 0.4
1AM.
CA 02538864 2012-06-11
63198-1511
60
Example 13 ¨ Angiogenesis Modulating Activity
Angiogenesis is the formation of new blood vessels from pre-existing
vessels. Angiogenesis is prominent in solid tumor formation and metastasis,
and is
part of the wound healing process. Pathological angiogenesis sometimes occurs
in
inappropriate anatomic locations, such as the retina or cornea, in response to
disease
and injury. Inhibition of angiogenesis could avoid the progression of
conditions of
inappropriate angiogenesis.
Tumor formation, for example, requires a network of blood vessels to sustain
the nutrient and oxygen supply for continued growth. Tumors in which
angiogenesis is important include most solid tumors and benign tumors, such as
acoustic neuroma, neurofibroma, trachoma, and pyogenic granulomas. Inhibition
of
angiogenesis could halt the growth of these tumors and the resultant damage
due to
the presence of the tumor.
There is a direct correlation between tumor microvessel density and the
incidence of metastasis. Tumor cells themselves can produce factors that
stimulate
the proliferation of endothelial cells and new capillary growth. Angiogenesis
is
important in two stages of tumor metastasis. The first stage where
angiogenesis
stimulation is important is in the vascularization of the primary tumor, which
allows
tumor cells to enter the blood stream and to circulate throughout the body.
After the
tumor cells have left the primary site, and have settled into the secondary,
metastatic
site, angiogenesis must occur before the metastasis can grow and expand.
Therefore, inhibiting angiogenesis could lead to the reduction or elimination
of
metastasis of tumors and possibly contain the neoplastic growth at the primary
site.
These observations have led to the investigation of anti-angiogenic agents as
possible therapeutic options for various cancers.
The angiogenesis modulating activity of representative compounds was assessed
in a rat aortic ring microvessel growth assay. Briefly, twelve-well tissue
culture plates
TM
were coated with 250 I of Matrigel (Becton-Dickinson, Bedford, MA) and
allowed to
gel for 30 mm at 37 C and 5% CO2. Thoracic aortas were excised from 8- to 10-
week-
old male Sprague Dawley rats. After careful removal of fibroadipose tissues,
the aortas
were cut into 1-mm-long cross-sections, placed on Matrigel-coated wells, and
covered
with an additional 250 1 of Matrigel. After the second layer of Matrigel had
set, the
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
61
rings were covered with EGM-II and incubated overnight at 37 C and 5% CO2. EGM-
II consists of endothelial cell basal medium (EBM-II; Clonetics, San Diego,
CA) plus
endothelial cell growth factors provided as the EGM-II Bulletkit (Clonetics).
The
culture medium was subsequently changed to EBM-II supplemented with 2% fetal
bovine serum, 0.25 tig/m1 amphotericin B, and 10 g/m1 gentamicin. Aortic rings
were
treated daily with either the vehicle (0.5% DMSO), carboxyamidotnazole (CAI,
12
gimp, thalidomide or thalidomide analogs (0.1-20 [ig/m1) for 4 days and
photographed
on the 5th day using a x2.5 objective. CM, a known antiangiogenic agent, was
used at
higher than clinically achievable concentration as a positive control.
Experiments were
repeated four times using aortas from four different rats. The area of
angiogenic
sprouting, reported in square pixels, was quantified using Adobe PhotoShop.
Further
details of the method are provided in Luzzio et al., J Med Chem.; 46:3793-9,
2003,
which is incorporated by reference herein. It should be understood that this
method can
be used as an assay to rapidly select compounds having a desired angiogenic or
anti-
angiogenic effect, for example, for use in the disclosed methods of treating a
subject.
Bar graphs showing the results of the angiogenesis assay for several
compounds are shown in FIGS. 2-11. For convenience, the structures of the
assayed
compounds also are presented in these figures.
FIG. 2 shows the angiogenic modulating activity of 1,3-Dioxo-2-(2-hydroxy-
6-methoxypyridin-3-y1)-isoindoline hydrobromide at several concentrations.
This
compound exhibited anti-angiogenic activity in the rat aortic ring assay at
all
concentrations tested.
FIG. 3 shows the angiogenic modulating activity of 2-(3-cyclohexeny1)-H-
isoindo1-1,3(21/)-dithione at several concentrations. This compounds exhibited
anti-
angiogenic activity at higher concentrations and angiogenic activity at lower
concentrations.
FIG. 4 shows the angiogenic modulating activity of 1-(2,6-Dithioxo-3-
piperidiny1)-1H-isoindole-1,3(21/)-dione at several concentrations. This
compound
exhibited anti-angiogenic activity at all concentrations tested.
FIG. 5 shows the angiogenic modulating activity of 3-Camphanic amino-2,6-
piperidinedione at several concentrations. This compound exhibited potent
angiogenic activity at all concentrations tested, making this compound
promising for
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
62
treating conditions where increased angiogenesis is desired, for example, as
an aid to
wound healing.
FIG. 6 shows the angiogenic modulating activity of Dithiophthalimide at
several concentrations. This compound exhibited angiogenic activity at all
concentrations tested.
FIG. 7 shows the angiogenic modulating activity of 2-(1,3-Dihydro-1-oxo-3-
thioxo-2H-isoindo1-2-y1)-pentanedioic acid at several concentrations. This
compound exhibited angiogenic activity at all concentrations tested.
FIG. 8 shows the angiogenic modulating activity of 2-(2-0xo-6-thioxo-3-
piperidiny1)-1H-isoindole-1,3(2H)-dione at several concentrations. This
compound
showed anti-angiogenic activity at higher concentration, and some angiogenic
activity at lower concentrations.
FIG. 9 shows the angiogenic modulating activity of 2,3-Dihydro-3-thioxo-2-
(2,6-dithioxo-3-piperidiny1)-1H-isoindo1-1-one at several concentrations. This
compound exhibited potent anti-antigiogenic activity at higher concentrations
and
angiogenic activity at lower concentrations.
FIG. 10 shows the angiogenic modulating activity of 2-Acetoxy-N-(2,6-
dioxopiperidin-3-yl)benzamide at several concentrations. At all concentrations
tested, this compound exhibited potent angiogenic activity.
FIG. 11 shows the angiogenic modulating activity of 1,3-Dioxo-2-(2,6-
dimethoxypyridin-3-y1)-isoindoline at several concentrations. This compound
exhibited
angiogenic activity at all concentrations tested.
In summary, the disclosed compounds exhibit a range of angiogenic modulating
activities ranging from potent inhibition of angiogenesis (anti-angiogenic
activity) to
potent stimulation of angiogenesis (angiogenic activity). Some compounds
exhibit both
angiogenic and anti-angiogenic activity in a dose-dependent manner. Those
compounds (or particular concentrations thereof) having angiogenic activity
are useful
for treating conditions or diseases where increasing angiogenesis is desirable
(for
example, wound healing) and those compounds (or particular concentrations
thereof)
having anti-angiogenic activity are useful for treating conditions or diseases
where
decreasing angiongenesis is desirable (for example, cancers, diabetic
retinopathy or
corneal neovascularization). Persons of ordinary skill in the art can use the
assay
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
63
described above (or other known angiogenic/anti-angiogenic activity assays) to
readily
determine amounts of the disclosed compounds that therapeutically effective
for
stimulating or inhibiting angio genesis as appropriate for a given subject's
condition.
Example 14 - Synthesis of 3-Camphanic amino-2,6-piperidinedione
A mixture of (+)-camphanic chloride (19 mg, 00868 mmol),
aminoglutarimide (21 mg, 0.0868 nunol) and Et3N ( 24 ill) in CHC13( 1 ml) was
stirred at room temperature for 16 hours. The solution was diluted with CHC13
,washed with saturated aqueous solution of NaHCO3, dried over Na2SO4,
concentrated and purified by chromatography ( silica gel, CH2C12 ; Et0Ac = 10:
1)
to give product (16 mg, 60.0% yield) as a colorless gel: 13CNMR ( CDC13 ) 8
172.6,
169.4, 168.6, 165.5, 90.3, 58.3, 53.3, 48.2, 47.6, 29.2, 28.2, 26.9, 22.7,
14.6, 7.6; MS
( CI / CH4 ) m/z 308 ( 1V1+ ). This compound exhibited angiogenic activity in
the
assay of Example 13.
Example 15 ¨ Synthesis of 3-Benzylimino-2-benzy1-2,3-dihydroisoindo1-1-one
A solution of Dimethyl 2-(1,3-dihydro-1-oxo-3-thioxo-2H-isoindo1-2-y1)-
pentanedioate (compound 208 of Example 11, 100mg, 0.311 mmol) and
benzylamine was stirred in a 50 C oil bath for 5 hours. The reaction mixture
was
partitioned between water and ethyl acetate. The organic layer was washed with
water, dried, and concentrated. The residue was purified by chromatography (
silica
gel, CH2C12) to give product as white crystals ( 60 mg, 59.0%): 11-1NMR
(CDC13) 8
7.10 ¨7.90 ( m, 10 H), 5.18 ( s, 2H), 4.95 ( s, 2H); 13C NMR ( CDC13 ) 8
167.8,
151.3, 140.6, 138.2, 133.5, 133.3, 132.1, 130.4, 130.1, 129.1, 128.8, 128.7,
128.5,
128.4, 127.9, 127.6, 127.5, 127.2, 126.0, 124.1, 53.9, 42.5; FAB-MS m/z 327
(M1I+). This compound exhibited angiogenic activity in the assay of Example
13.
CA 02538864 2012-06-11
63198-1511
64
Example 16 - Thionation
Although many of the disclosed compounds are illustrated without thionyl
groups in their structures, it is to be understood that any of the carbonyl
groups shown
in the structures of the disclosed compounds may be converted into
thiocarbonyl
groups, and that such thio-derivatives are part of this disclosure. Thionation
may be
accomplished by any known method. Particular methods of thionation include use
of
phosphorus pentasulfide, hydrogen sulfide, 0,0-diethyldithiophosphonic acid,
boron
sulfide, silicon disulfide and elemental sulfur in HMPA. However, a
particularly
convenient method of thionation is the use of 2,4-bis(p-methoxypheny1)-1,3-
dithiadiphosphetane-2,4-disulfide and its derivatives (generically "Lawesson's
Reagents"). These reagents are described in Cava and Levinson, "Thionation
Reactions
of Lawesson's Reagents," Tetrahedron, 41: 5061-5087, 1985.
Example 17 ¨ Pharmaceutical Compositions
The disclosed pharmaceutical compositions can be in the form of tablets,
capsules, powders, granules, lozenges, liquid or gel preparations, such as
oral,
topical, or sterile parenteral solutions or suspensions (e.g., eye or ear
drops, throat or
nasal sprays, etc.), transdermal patches, and other forms known in the art.
Pharmaceutical compositions can be administered systemically or locally in
any manner appropriate to the treatment of a given condition, including
orally,
parenterally, rectally, nasally, buccally, vaginally, topically, optically, by
inhalation
spray, or via an implanted reservoir. The term "parenterally" as used herein
includes, but is not limited to subcutaneous, intravenous, intramuscular,
intrasternal,
intrasynovial, intrathecal, intrahepatic, intralesional, and intracranial
administration,
for example, by injection or infusion. For treatment of the central nervous
system,
the pharmaceutical compositions may readily penetrate the blood-brain barrier
when
peripherally or intraventricularly administered.
Pharmaceutically acceptable carriers include, but are not limited to, ion
exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as
human
serum albumin), buffers (such as phosphates), glycine, sorbic acid, potassium
sorb ate, partial glyceride mixtures of saturated vegetable fatty acids,
water, salts or
WO 2005/028436 CA 02538864 2006-03-09PCT/US2004/030506
65
electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene
glycol,
sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-
polyoxypropylene-block polymers, polyethylene glycol, and wool fat.
Tablets and capsules for oral administration can be in a form suitable for
unit
dose presentation and can contain conventional pharmaceutically acceptable
excipients. Examples of these include binding agents such as syrup, acacia,
gelatin,
sorbitol, tragacanth, and polyvinylpyrrolidone; fillers such as lactose,
sugar, corn
starch, calcium phosphate, sorbitol, or glycine; tableting lubricants, such as
magnesium stearate, talc, polyethylene glycol, or silica; disintegrants, such
as potato
starch; and dispersing or wetting agents, such as sodium lauryl sulfate. Oral
liquid
preparations can be in the form of, for example, aqueous or oily suspensions,
solutions, emulsions, syrups or elixirs, or can be presented as a dry product
for
reconstitution with water or other suitable vehicle before use.
The pharmaceutical compositions can also be administered parenterally in a
sterile aqueous or oleaginous medium. The composition can be dissolved or
suspended in a non-toxic parenterally-acceptable diluent or solvent, e.g., as
a
solution in 1,3-butanediol. Commonly used vehicles and solvents include water,
physiological saline, Hank's solution, Ringer's solution, and sterile, fixed
oils,
including synthetic mono- or di-glycerides, etc. For topical application, the
drug
may be made up into a solution, suspension, cream, lotion, or ointment in a
suitable
aqueous or non-aqueous vehicle. Additives may also be included, for example,
buffers such as sodium metabisulphite or disodium edeate; preservatives such
as
bactericidal and fungicidal agents, including phenyl mercuric acetate or
nitrate,
benzalkonium chloride or chlorhexidine, and thickening agents, such as
hypromellose.
The dosage unit involved depends, for example, on the condition treated,
nature of the formulation, nature of the condition, embodiment of the claimed
pharmaceutical compositions, mode of administration, and condition and weight
of
the patient. Dosage levels are typically sufficient to achieve a tissue
concentration at
the site of action that is at least the same as a concentration that has been
shown to
CA 02538864 2012-06-11
63198-1511 =
66
be active in vitro, in vivo, or in tissue culture. For example, a dosage of
about 0.1
p.g/kg body weight/day to about 1000 mg/kg body weight/day, for example, a
dosage of about 1 p.g/kg body weight/day to about 1000 jig/kg body weight/day,
such as a dosage of about 5 fig/kg body weight/day to about 500 pig/kg body
weight/day can be useful for treatment of a particular condition.
The compounds can be used in the form of pharmaceutically acceptable salts
derived from inorganic or organic acids and bases, including, but not limited
to:
acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate,
butyrate,
citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate,
hemisulfate, heptano ate, hexanoate, hydrochloride, hydrobromide, hydroiodide,
2-
hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-
naphthalenesulfonate,
nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate,
picrate,
pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and
undecanoate.
Base salts include, but are not limited to, ammonium salts, alkali metal salts
(such as
sodium and potassium salts), alkaline earth metal salts (such as calcium and
magnesium salts), salts with organic bases (such as dicyclohexylamine salts),
N-
methyl-D-glucamine, and salts with amino acids (such as arginine, lysine,
etc.).
Basic nitrogen-containing groups can be quatemized, for example, with such
agents
as C1-8 alkyl halides (such as methyl, ethyl, propyl, and butyl chlorides,
bromides,
and iodides), dialkyl sulfates (such as dimethyl, diethyl, dibutyl, an diamyl
sulfates),
long-chain halides (such as decyl, lauryl, myristyl, and stearyl chlorides,
bromides,
and iodides), aralkyl halides (such as benzyl and phenethyl bromides), etc.
Water or
oil-soluble or dispersible products are produced thereby.
Pharmaceutical compositions can be included in a kit accompanied by
instructions for intended use, for example instructions required by a
pharmaceutical
regulatory agency, such as the Food and Drug Administration in the United
State. s.
